{"protocolSection":{"identificationModule":{"nctId":"NCT00390806","orgStudyIdInfo":{"id":"HYT105962"},"organization":{"fullName":"GlaxoSmithKline","class":"INDUSTRY"},"briefTitle":"Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer","officialTitle":"A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared With WBRT Alone in Patients With Brain Metastases From Non-Small Cell Lung Cancer"},"statusModule":{"statusVerifiedDate":"2013-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2006-12"},"primaryCompletionDateStruct":{"date":"2012-07","type":"ACTUAL"},"completionDateStruct":{"date":"2013-09","type":"ACTUAL"},"studyFirstSubmitDate":"2006-10-19","studyFirstSubmitQcDate":"2006-10-19","studyFirstPostDateStruct":{"date":"2006-10-20","type":"ESTIMATED"},"resultsFirstSubmitDate":"2013-03-08","resultsFirstSubmitQcDate":"2013-12-05","resultsFirstPostDateStruct":{"date":"2014-01-20","type":"ESTIMATED"},"lastUpdateSubmitDate":"2013-12-05","lastUpdatePostDateStruct":{"date":"2014-01-20","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"GlaxoSmithKline","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The current prognosis for patients with metastatic brain cancer from NSCLC is very poor. The current standard treatment for this disease is radiation therapy to the brain. The goal of the current study is to test whether the combination of orally administered HYCAMTIN capsules and whole brain radiation therapy will prolong the survival time of patients with this potentially serious condition."},"conditionsModule":{"conditions":["Lung Cancer, Non-Small Cell"],"keywords":["Brain metastases from Non-Small Cell Lung Cancer","Brain metastases brain tumor lung cancer oral chemotherapy HYCAMTIN topotecan NSCLC WBRT whole brain radiation"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":472,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"topotecan plus radiation","type":"EXPERIMENTAL","description":"topotecan 1.1 mg/m2 followed by whole brain radiation 3 Gy/day for 10 days, followed by optional continuation therapy with topotecan 2.3 mg/m2 for 5 days Q21 days as monotherapy.","interventionNames":["Drug: HYCAMTIN, oral capsules","Radiation: Radiation"]},{"label":"Whole brain radiation","type":"ACTIVE_COMPARATOR","description":"Whole brain radiation 3 Gy/day for 10 days","interventionNames":["Radiation: Radiation"]}],"interventions":[{"type":"DRUG","name":"HYCAMTIN, oral capsules","description":"topotecan oral capsules 1.1 mg/m2","armGroupLabels":["topotecan plus radiation"],"otherNames":["HYCAMTIN","oral capsules"]},{"type":"RADIATION","name":"Radiation","description":"Whole brain radiation","armGroupLabels":["Whole brain radiation","topotecan plus radiation"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Overall Survival","description":"Overall survival is defined as the time from randomization until the date of death due to any cause. The date of last contact was used for those participants who had not died or were lost to follow-up. These participants were classified as having been censored.","timeFrame":"From the time of Randomization until the date of death due to any cause (up to 195 weeks)"}],"secondaryOutcomes":[{"measure":"Six-month Survival","description":"Six-month survival is defined as the percentage of participants alive at 6 months following randomization. The date of last contact was used for those participants who had not died or were lost to follow-up. These participants were classified as having been censored.","timeFrame":"Month 6"},{"measure":"Number of Participants With a Complete Response (CR) or a Partial Response (PR) (Central Nervous System [CNS]-Radiologic)","description":"The number of participants achieving either a CR or PR, per World Health Organization (WHO) Criteria, in the CNS was assessed. CR is defined as the complete disappearance of all known measurable (Must be accurately measured in \\>=1 dimension) and nonmeasurable disease, without clinical, laboratory, or radiological evidence of recurrence for at least 4 weeks. CR may have been defined in participants with measurable and/or non-measurable disease at Screening. PR is defined as at least a 50% decrease in the sum of the products of the greatest length and perpendicular width of all measurable disease with no clear increase in nonmeasurable disease in participants without measurable disease. In both cases, there must have been no appearance of new disease, and no clinical, laboratory, or radiological evidence of disease progression for at least 4 weeks. Assessment of response was performed by the investigator and was based on unconfirmed responses.","timeFrame":"From the time of Randomization until the time of CR or PR (up to 75 weeks)"},{"measure":"Time to Response (TTR) (CNS-radiologic)","description":"TTR is defined as the time from Randomization until the first documented evidence of CR or PR in the CNS. CR is defined as the complete disappearance of all known measurable (Must be accurately measured in \\>=1 dimension) and nonmeasurable disease, without clinical, laboratory, or radiological evidence of recurrence for at least 4 weeks. CR may have been defined in participants with measurable and/or non-measurable disease at Screening. PR is defined as at least a 50% decrease in the sum of the products of the greatest length and perpendicular width of all measurable disease with no clear increase in nonmeasurable disease in participants without measurable disease. In both cases, there must have been no appearance of new disease, and no clinical, laboratory, or radiological evidence of disease progression for at least 4 weeks. Assessment of response was performed by the investigator and was based on unconfirmed responses.","timeFrame":"From the time of Randomization until the first documented evidence of CR or PR (up to 75 weeks)"},{"measure":"Time to Progression (TTP) (CNS-radiologic)","description":"TTP is defined as the time from Randomization until the first documented sign of disease progression in the CNS. Progressive disease (PD) is defined as an increase \\>=25% in any measurable lesion or, in participants with non-measurable disease only, an estimation of an increase \\>=25%. In both cases, determination of progression included the appearance of any new lesions, or signification worsening of conditions presumed to be related to malignancy. Participants with clinical or laboratory evidence of possible disease progression were to be evaluated radiologically. TTP was analyzed with censoring for extended loss to follow-up to account for two or more missed assessments before a TTP event. The date of the last adequate CNS assessment before extended loss to follow-up was used for censored participants.","timeFrame":"From the time of Randomization until the first documented sign of disease progression (up to 75 weeks)"},{"measure":"Time to Progression (TTP) (All Sites of Disease-radiologic)","description":"TTP is defined as the time from Randomization until the first documented sign of disease progression in all sites of disease. Progressive disease (PD) is defined as an increase \\>=25% in any measurable lesion or, in participants with non-measurable disease only, an estimation of an increase \\>=25%. In both cases, determination of progression included the appearance of any new lesions, or signification worsening of conditions presumed to be related to malignancy. Participants with clinical or laboratory evidence of possible disease progression were to be evaluated radiologically. TTP was analyzed with censoring for extended loss to follow-up to account for two or more missed assessments before a TTP event. The date of the last adequate CNS assessment before extended loss to follow-up was used for censored participants.","timeFrame":"From the time of Randomization until the first documented sign of disease progression (up to 75 weeks)"},{"measure":"Number of Participants Who Ranked Each Individual Indicated Neurological Sign and Symptom as None, Mild, Moderate, or Severe at Months 1 and 3","description":"Neurological signs and symptoms data were derived from a participant-reported diary. The participants were asked to assess the following signs and symptoms on a scale of none, mild, moderate, or severe at Months 1 and 3: headache, problems with balance/coordination (PB/C), leg weakness, arm weakness, loss of feeling/numbness (LofF/N), speech difficulty (SD), confusion, loss of memory (LofM), drowsiness, nausea, vomiting, dizziness, visual problems (VP), seizures, leg/ankle swelling (L/AS), heart burn, difficulty sleeping (DS), tiredness, and appetite/weight gain (A/WG).","timeFrame":"Months 1 and 3"},{"measure":"Number of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Level of Consciousness at Baseline, Month 1, and Month 3","description":"The investigator assessed participants for the neurological sign and symptom of level of consciousness and assigned each participant to one of the following categories: normal; somnolence or sedation not interfering with function (not intefering); somnolence or sedation interfering with function, but not activities of daily living (ADLs) (interfering); obtundation or stupor, difficult to arouse, inteferring with ADLs (obtundation or stupor); coma.","timeFrame":"Baseline, Month 1, and Month 3"},{"measure":"Number of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Headache at Baseline, Month 1, and Month 3","description":"The investigator (per Common Terminology Criteria for Adverse Events \\[CTCAE\\], version 3.0) assessed participants for headache and assigned each participant to one of the following categories: absent, Grade (G) 1, G 2, G 3, G 4, and G 5. Grade refers to the severity of the AE. The CTCAE displays G 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: G 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; G 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental ADL; G 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self care ADL; G 4: life-threatening consequences, urgent intervention indicated; G 5: death related to AE.","timeFrame":"Baseline, Month 1, and Month 3"},{"measure":"Number of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Dizziness/Lightheadedness at Baseline, Month 1, and Month 3","description":"The investigator (per CTCAE, version 3.0) assessed participants for dizziness/lightheadedness and assigned each participant to one of the following categories: absent, G 1, G 2, G 3, G 4, and G 5. Grade refers to the severity of the AE. The CTCAE displays G 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: G 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; G 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental ADL; G 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self care ADL; G 4: life-threatening consequences, urgent intervention indicated; G 5: death related to AE.","timeFrame":"Baseline, Month 1, and Month 3"},{"measure":"Number of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Vertigo at Baseline, Month 1, and Month 3","description":"The investigator (per CTCAE, version 3.0) assessed participants for vertigo and assigned each participant to one of the following categories: absent, G 1, G 2, G 3, G 4, and G 5. Grade refers to the severity of the AE. The CTCAE displays G 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: G 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; G 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental ADL; G 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self care ADL; G 4: life-threatening consequences, urgent intervention indicated; G 5: death related to AE.","timeFrame":"Baseline, Month 1, and Month 3"},{"measure":"Number of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Nausea/Vomiting at Baseline, Month 1, and Month 3","description":"The investigator (per CTCAE, version 3.0) assessed participants for nausea/vomiting and assigned each participant to one of the following categories: absent, G 1, G 2, G 3, G 4, and G 5. Grade refers to the severity of the AE. The CTCAE displays G 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: G 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; G 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental ADL; G 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self care ADL; G 4: life-threatening consequences, urgent intervention indicated; G 5: death related to AE.","timeFrame":"Baseline, Month 1, and Month 3"},{"measure":"Number of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Visual Problem at Baseline, Month 1, and Month 3","description":"The investigator (per CTCAE, version 3.0) assessed participants for visual problem and assigned each participant to one of the following categories: absent, G 1, G 2, G 3, G 4, and G 5. Grade refers to the severity of the AE. The CTCAE displays G 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: G 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; G 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental ADL; G 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self care ADL; G 4: life-threatening consequences, urgent intervention indicated; G 5: death related to AE.","timeFrame":"Baseline, Month 1, and Month 3"},{"measure":"Number of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Seizure at Baseline, Month 1, and Month 3","description":"The investigator (per CTCAE, version 3.0) assessed participants for seizure and assigned each participant to one of the following categories: absent, G 1, G 2, G 3, G 4, and G 5. Grade refers to the severity of the AE. The CTCAE displays G 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: G 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; G 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental ADL; G 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self care ADL; G 4: life-threatening consequences, urgent intervention indicated; G 5: death related to AE.","timeFrame":"Baseline, Month 1, and Month 3"},{"measure":"Number of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Other Neurological Symptoms at Baseline, Month 1, and Month 3","description":"The investigator (per CTCAE, version 3.0) assessed participants for other neurological symptoms and assigned each participant to one of the following categories: absent, G 1, G 2, G 3, G 4, and G 5. Grade refers to the severity of the AE. The CTCAE displays G 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: G 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; G 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental ADL; G 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self care ADL; G 4: life-threatening consequences, urgent intervention indicated; G 5: death related to AE.","timeFrame":"Baseline, Month 1, and Month 3"},{"measure":"Number of Participants With the Indicated Investigator Assessment of Cranial Nerves II-XII at Baseline, Month 1, and Month 3","description":"The investigator assessed participants' status of cranial nerves II-XII and assigned each participant to one of the following categories: normal; present, not interfering with ADLs; present, interfering with ADLs; life threatening, disabling.","timeFrame":"Baseline, Month 1, and Month 3"},{"measure":"Number of Participants With the Indicated Investigator Assessment of Language (Dysphasia or Aphasia) at Baseline, Month 1, and Month 3","description":"The investigator assessed participants' status of language (dysphasia or aphasia) and assigned each participant to one of the following categories: absent; awareness of receptive or expressive aphasia, not impairing ability to communicate (not impaired); receptive or expressive dysphasia, impairing ability to communicate (impaired); inability to communicate (unable).","timeFrame":"Baseline, Month 1, and Month 3"},{"measure":"Number of Participants With the Indicated Investigator Assessment of Strength (Right Upper Extremity) at Baseline, Month 1, and Month 3","description":"The investigator assessed participants' status of strength (right upper extremity) and assigned each participant to one of the following categories: normal; Grade 1, asymptomatic with weakness on physical examination; Grade 2, symptomatic and interfering with function, but not interfering with ADLs; Grade 3, symptomatic and interfering with ADLs; Grade 4: bedridden or disabling.","timeFrame":"Baseline, Month 1, and Month 3"},{"measure":"Number of Participants With the Indicated Investigator Assessment of Strength (Left Upper Extremity) at Baseline, Month 1, and Month 3","description":"The investigator assessed participants' status of strength (left upper extremity) and assigned each participant to one of the following categories: normal; Grade 1, asymptomatic with weakness on physical examination; Grade 2, symptomatic and interfering with function, but not interfering with ADLs; Grade 3, symptomatic and interfering with ADLs; Grade 4: bedridden or disabling.","timeFrame":"Baseline, Month 1, and Month 3"},{"measure":"Number of Participants With the Indicated Investigator Assessment of Strength (Right Lower Extremity) at Baseline, Month 1, and Month 3","description":"The investigator assessed participants' status of strength (right lower extremity) and assigned each participant to one of the following categories: normal; Grade 1, asymptomatic with weakness on physical examination; Grade 2, symptomatic and interfering with function, but not interfering with ADLs; Grade 3, symptomatic and interfering with ADLs; Grade 4: bedridden or disabling.","timeFrame":"Baseline, Month 1, and Month 3"},{"measure":"Number of Participants With the Indicated Investigator Assessment of Strength (Left Lower Extremity) at Baseline, Month 1, and Month 3","description":"The investigator assessed participants' status of strength (left lower extremity) and assigned each participant to one of the following categories: normal; Grade 1, asymptomatic with weakness on physical examination; Grade 2, symptomatic and interfering with function, but not interfering with ADLs; Grade 3, symptomatic and interfering with ADLs; Grade 4: bedridden or disabling.","timeFrame":"Baseline, Month 1, and Month 3"},{"measure":"Number of Participants With the Indicated Investigator Assessment of Sensation at Baseline, Month 1, and Month 3","description":"The investigator assessed participants' status of sensation and assigned each participant to one of the following categories: normal; loss of deep tendon reflexes or paresthesia, but not interfering with function (not interfering with function); objective sensory loss or paresthesia interfering with function, but not interfering with ADLs (interfering with function); sensory loss or paresthesia interfering with ADLs (intefering with ADLs); permanent sensory loss that interferes with function (permanent sensory loss).","timeFrame":"Baseline, Month 1, and Month 3"},{"measure":"Number of Participants With the Indicated Investigator Assessment of Ataxia (Right Upper Extremity: Finger to Nose Testing) at Baseline, Month 1, and Month 3","description":"The investigator assessed participants' status of ataxia (right upper extremity: finger to nose testing) and assigned each participant to one of the following categories: normal; Grade 1, asymptomatic but abnormal on physical examination, and not interfering with function; Grade 2, mild symptoms interfering with function, but not interfering with ADLs; Grade 3, moderate symptoms interfering with ADLs; Grade 4, bedridden or disabling.","timeFrame":"Baseline, Month 1, and Month 3"},{"measure":"Number of Participants With the Indicated Investigator Assessment of Ataxia (Left Upper Extremity: Finger to Nose Testing) at Baseline, Month 1, and Month 3","description":"The investigator assessed participants' status of ataxia (left upper extremity: finger to nose testing) and assigned each participant to one of the following categories: normal; Grade 1, asymptomatic but abnormal on physical examination, and not interfering with function; Grade 2, mild symptoms interfering with function, but not interfering with ADLs; Grade 3, moderate symptoms interfering with ADLs; Grade 4, bedridden or disabling.","timeFrame":"Baseline, Month 1, and Month 3"},{"measure":"Number of Participants With the Indicated Investigator Assessment of Ataxia (Gait) at Baseline, Month 1, and Month 3","description":"The investigator assessed participants' status of ataxia (gait) and assigned each participant to one of the following categories: normal; Grade 1, asymptomatic but abnormal on physical examination, and not interfering with function; Grade 2, mild symptoms interfering with function, but not interfering with ADLs; Grade 3, moderate symptoms interfering with ADLs; Grade 4, bedridden or disabling.","timeFrame":"Baseline, Month 1, and Month 3"},{"measure":"Number of Participants With the Indicated Investigator Assessment of Ataxia (Balance) at Baseline, Month 1, and Month 3","description":"The investigator assessed participants' status of ataxia (balance) and assigned each participant to one of the following categories: normal; Grade 1, asymptomatic but abnormal on physical examination, and not interfering with function; Grade 2, mild symptoms interfering with function, but not interfering with ADLs; Grade 3, moderate symptoms interfering with ADLs; Grade 4, bedridden or disabling.","timeFrame":"Baseline, Month 1, and Month 3"},{"measure":"Number of Participants With Any Adverse Event (AE; Both Serious and Non-serious) or Serious Adverse Event (SAE)","description":"An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect. For a list of all SAEs and AEs, see the SAE/AE module of this results summary.","timeFrame":"From Randomization until the last clinic visit associated with the study, up until 35 days after the start of the last course of treatment (up to 75 weeks)"},{"measure":"Number of Participants With the Indicated Worst-case Change From Baseline in the Indicated Chemistry Parameters With Respect to the Normal Range","description":"The worst-case change from Baseline in chemistry parameters was measured as decrease to low (DTL), change to normal or no change (CTN/NC), or increase to high (ITH). The worst-case change value could have been measured at any point during the on-therapy period. Participants are counted twice if the participant \"Decreased to Low\" and \"Increased to High\" during the on-therapy period.","timeFrame":"From Randomization until the last clinic visit associated with the study, up until 35 days after the start of the last course of treatment (up to 75 weeks)"},{"measure":"Lesion Assessment and Measurement","description":"Lesions were assessed per WHO criteria. For lesion assessment data, see the outcome measure entitled \"Number of participants with a complete response (CR) or a partial response (PR) (central nervous system \\[CNS\\]-radiologic).\"","timeFrame":"From the time of Randomization until the time of CR or PR (up to 75 weeks)"},{"measure":"Brain Symptoms","description":"Brain symptoms were assessed as the number of participants with neurological signs and symptoms. For brain symptom data, see the outcome measures entitled \"Number of participants with the indicated investigator assessment for the neurological sign and symptom of X at Baseline, Month 1, and Month 3.\"","timeFrame":"Baseline, Month 1, and Month 3"},{"measure":"Number of Participants Who Died or Progressed","description":"Disease-related events were measured as the number of participants who died or progressed. Progressive disease (PD) is defined as an increase \\>=25% in any measurable lesion or, in participants with non-measurable disease only, an estimation of an increase \\>=25%. In both cases, determination of progression included the appearance of any new lesions, or signification worsening of conditions presumed to be related to malignancy. Participants with clinical or laboratory evidence of possible disease progression were to be evaluated radiologically. Data were analyzed with censoring for extended loss to follow-up to account for two or more missed assessments before an event. The date of the last adequate CNS assessment before extended loss to follow-up was used for censored participants.","timeFrame":"From Randomization until the last clinic visit associated with the study, up until 35 days after the start of the last course of treatment (up to 75 weeks)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* At least one measurable cancerous lesion in the brain from primary non-small cell lung cancer (NSCLC)\n* Must have received previous chemotherapy\n* Must be 18 years of age of greater\n* Must be Easter Cooperative Oncology Group (ECOG) Performance Status 0, 1, 2\n* At least 2 weeks must have elapsed since any surgery\n* At least 4 weeks must have elapsed since any radiation to a non-CNS site\n* Must have adequate bone marrow, renal, and live capacities\n* Women must be of non-childbearing potential or practice adequate birth control\n* Males must practice adequate methods of birth control\n* Must sign written informed consent\n\nExclusion criteria:\n\n* Previous whole brain radiation therapy\n* Prior treatment with topotecan\n* Investigational agent within 30 days or 5 half-live\n* Concomitant therapy with inhibitors of breast cancer resistance protein (BCRP) or P-glycoprotein such as erlotinib or gefitinib\n* Primary or secondary immunodeficiencies\n* Gastrointestinal conditions that affect GI absorption or motility\n* Uncontrolled emesis\n* Brain metastasis at time of initial diagnosis of NSCLC\n* History of other malignancy except in situ carcinoma of cervix; nonmelanomatous skin cancer, low grade prostate cancer\n* Pregnant or intending to become pregnant or intending to father a baby\n* Any severe concurrent medical condition that could affect compliance.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"GSK Clinical Trials","affiliation":"GlaxoSmithKline","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"GSK Investigational Site","city":"Birmingham","state":"Alabama","zip":"35294","country":"United States","geoPoint":{"lat":33.52066,"lon":-86.80249}},{"facility":"GSK Investigational Site","city":"Glendale","state":"Arizona","zip":"85304","country":"United States","geoPoint":{"lat":33.53865,"lon":-112.18599}},{"facility":"GSK Investigational Site","city":"Hot Springs","state":"Arkansas","zip":"71913","country":"United States","geoPoint":{"lat":34.5037,"lon":-93.05518}},{"facility":"GSK Investigational Site","city":"Anaheim","state":"California","zip":"92801","country":"United States","geoPoint":{"lat":33.83529,"lon":-117.9145}},{"facility":"GSK Investigational Site","city":"Duarte","state":"California","zip":"91010-3000","country":"United States","geoPoint":{"lat":34.13945,"lon":-117.97729}},{"facility":"GSK Investigational Site","city":"Pleasant Hill","state":"California","zip":"94523","country":"United States","geoPoint":{"lat":37.94798,"lon":-122.0608}},{"facility":"GSK Investigational Site","city":"Aurora","state":"Colorado","zip":"80012","country":"United States","geoPoint":{"lat":39.72943,"lon":-104.83192}},{"facility":"GSK Investigational Site","city":"Lakeland","state":"Florida","zip":"33805","country":"United States","geoPoint":{"lat":28.03947,"lon":-81.9498}},{"facility":"GSK Investigational Site","city":"Tampa","state":"Florida","zip":"33606","country":"United States","geoPoint":{"lat":27.94752,"lon":-82.45843}},{"facility":"GSK Investigational Site","city":"Tampa","state":"Florida","zip":"33612","country":"United States","geoPoint":{"lat":27.94752,"lon":-82.45843}},{"facility":"GSK Investigational Site","city":"Chicago","state":"Illinois","zip":"60612","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}},{"facility":"GSK Investigational Site","city":"Elk Grove Village","state":"Illinois","zip":"60007","country":"United States","geoPoint":{"lat":42.00392,"lon":-87.97035}},{"facility":"GSK Investigational Site","city":"Galesburg","state":"Illinois","zip":"61401","country":"United States","geoPoint":{"lat":40.94782,"lon":-90.37124}},{"facility":"GSK Investigational Site","city":"Park Ridge","state":"Illinois","zip":"60068","country":"United States","geoPoint":{"lat":42.01114,"lon":-87.84062}},{"facility":"GSK Investigational Site","city":"Rockford","state":"Illinois","zip":"61108","country":"United States","geoPoint":{"lat":42.27113,"lon":-89.094}},{"facility":"GSK Investigational Site","city":"Skokie","state":"Illinois","zip":"60077","country":"United States","geoPoint":{"lat":42.03336,"lon":-87.73339}},{"facility":"GSK Investigational Site","city":"Indianapolis","state":"Indiana","zip":"46227","country":"United States","geoPoint":{"lat":39.76838,"lon":-86.15804}},{"facility":"GSK Investigational Site","city":"Westwood","state":"Kansas","zip":"66205","country":"United States","geoPoint":{"lat":39.04056,"lon":-94.6169}},{"facility":"GSK Investigational Site","city":"Paducah","state":"Kentucky","zip":"42003","country":"United States","geoPoint":{"lat":37.08339,"lon":-88.60005}},{"facility":"GSK Investigational Site","city":"Metairie","state":"Louisiana","zip":"70006","country":"United States","geoPoint":{"lat":29.98409,"lon":-90.15285}},{"facility":"GSK Investigational Site","city":"Minneapolis","state":"Minnesota","zip":"55455","country":"United States","geoPoint":{"lat":44.97997,"lon":-93.26384}},{"facility":"GSK Investigational Site","city":"Jackson","state":"Mississippi","zip":"39216","country":"United States","geoPoint":{"lat":32.29876,"lon":-90.18481}},{"facility":"GSK Investigational Site","city":"Columbia","state":"Missouri","zip":"65201","country":"United States","geoPoint":{"lat":38.95171,"lon":-92.33407}},{"facility":"GSK Investigational Site","city":"Kansas City","state":"Missouri","zip":"64154","country":"United States","geoPoint":{"lat":39.09973,"lon":-94.57857}},{"facility":"GSK Investigational Site","city":"Lincoln","state":"Nebraska","zip":"68510","country":"United States","geoPoint":{"lat":40.8,"lon":-96.66696}},{"facility":"GSK Investigational Site","city":"Las Vegas","state":"Nevada","zip":"89106","country":"United States","geoPoint":{"lat":36.17497,"lon":-115.13722}},{"facility":"GSK Investigational Site","city":"Las Vegas","state":"Nevada","zip":"89135","country":"United States","geoPoint":{"lat":36.17497,"lon":-115.13722}},{"facility":"GSK Investigational Site","city":"Albuquerque","state":"New Mexico","zip":"87109","country":"United States","geoPoint":{"lat":35.08449,"lon":-106.65114}},{"facility":"GSK Investigational Site","city":"Albany","state":"New York","zip":"12206","country":"United States","geoPoint":{"lat":42.65258,"lon":-73.75623}},{"facility":"GSK Investigational Site","city":"Buffalo","state":"New York","zip":"14215-1199","country":"United States","geoPoint":{"lat":42.88645,"lon":-78.87837}},{"facility":"GSK Investigational Site","city":"Buffalo","state":"New York","zip":"14215","country":"United States","geoPoint":{"lat":42.88645,"lon":-78.87837}},{"facility":"GSK Investigational Site","city":"The Bronx","state":"New York","zip":"10467","country":"United States","geoPoint":{"lat":40.84985,"lon":-73.86641}},{"facility":"GSK Investigational Site","city":"Columbus","state":"Ohio","zip":"43235","country":"United States","geoPoint":{"lat":39.96118,"lon":-82.99879}},{"facility":"GSK Investigational Site","city":"Eugene","state":"Oregon","zip":"97401-8122","country":"United States","geoPoint":{"lat":44.05207,"lon":-123.08675}},{"facility":"GSK Investigational Site","city":"Charleston","state":"South Carolina","zip":"29403","country":"United States","geoPoint":{"lat":32.77632,"lon":-79.93275}},{"facility":"GSK Investigational Site","city":"Bedford","state":"Texas","zip":"76022","country":"United States","geoPoint":{"lat":32.84402,"lon":-97.14307}},{"facility":"GSK Investigational Site","city":"Corpus Christi","state":"Texas","zip":"78412","country":"United States","geoPoint":{"lat":27.80058,"lon":-97.39638}},{"facility":"GSK Investigational Site","city":"Dallas","state":"Texas","zip":"75320-2510","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"GSK Investigational Site","city":"Duncanville","state":"Texas","zip":"75137","country":"United States","geoPoint":{"lat":32.6518,"lon":-96.90834}},{"facility":"GSK Investigational Site","city":"Fort Worth","state":"Texas","zip":"76104","country":"United States","geoPoint":{"lat":32.72541,"lon":-97.32085}},{"facility":"GSK Investigational Site","city":"Lubbock","state":"Texas","zip":"79415","country":"United States","geoPoint":{"lat":33.57786,"lon":-101.85517}},{"facility":"GSK Investigational Site","city":"Sherman","state":"Texas","zip":"75090","country":"United States","geoPoint":{"lat":33.63566,"lon":-96.60888}},{"facility":"GSK Investigational Site","city":"Sugarland","state":"Texas","zip":"77479","country":"United States"},{"facility":"GSK Investigational Site","city":"Everett","state":"Washington","zip":"98201","country":"United States","geoPoint":{"lat":47.97898,"lon":-122.20208}},{"facility":"GSK Investigational Site","city":"Vancouver","state":"Washington","zip":"98684","country":"United States","geoPoint":{"lat":45.63873,"lon":-122.66149}},{"facility":"GSK Investigational Site","city":"Madison","state":"Wisconsin","zip":"53792","country":"United States","geoPoint":{"lat":43.07305,"lon":-89.40123}},{"facility":"GSK Investigational Site","city":"Moncton","state":"New Brunswick","zip":"E1C 8X3","country":"Canada","geoPoint":{"lat":46.09454,"lon":-64.7965}},{"facility":"GSK Investigational Site","city":"Hamilton","state":"Ontario","zip":"L8V 5C2","country":"Canada","geoPoint":{"lat":43.25011,"lon":-79.84963}},{"facility":"GSK Investigational Site","city":"Kingston","state":"Ontario","zip":"K7L 5P9","country":"Canada","geoPoint":{"lat":44.22976,"lon":-76.48098}},{"facility":"GSK Investigational Site","city":"London","state":"Ontario","zip":"N6A 4L6","country":"Canada","geoPoint":{"lat":42.98339,"lon":-81.23304}},{"facility":"GSK Investigational Site","city":"Toronto","state":"Ontario","zip":"M5G 2M9","country":"Canada","geoPoint":{"lat":43.70643,"lon":-79.39864}},{"facility":"GSK Investigational Site","city":"Greenfield Park","state":"Quebec","zip":"J4V 2H1","country":"Canada","geoPoint":{"lat":45.48649,"lon":-73.46223}},{"facility":"GSK Investigational Site","city":"Montreal","state":"Quebec","zip":"H1T 2M4","country":"Canada","geoPoint":{"lat":45.50884,"lon":-73.58781}},{"facility":"GSK Investigational Site","city":"Montreal","state":"Quebec","zip":"H2L 4M1","country":"Canada","geoPoint":{"lat":45.50884,"lon":-73.58781}},{"facility":"GSK Investigational Site","city":"Québec","state":"Quebec","zip":"G1R 2J6","country":"Canada","geoPoint":{"lat":46.81228,"lon":-71.21454}},{"facility":"GSK Investigational Site","city":"Sherbrooke","state":"Quebec","zip":"J1H 5N4","country":"Canada","geoPoint":{"lat":45.40008,"lon":-71.89908}},{"facility":"GSK Investigational Site","city":"Budapest","zip":"1529","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"facility":"GSK Investigational Site","city":"Csorna","zip":"9300","country":"Hungary","geoPoint":{"lat":47.61155,"lon":17.25012}},{"facility":"GSK Investigational Site","city":"Győr","zip":"9024","country":"Hungary","geoPoint":{"lat":47.68333,"lon":17.63512}},{"facility":"GSK Investigational Site","city":"Gyula","zip":"5703","country":"Hungary","geoPoint":{"lat":46.65,"lon":21.28333}},{"facility":"GSK Investigational Site","city":"Mátraháza","zip":"3233","country":"Hungary","geoPoint":{"lat":47.87124,"lon":19.97981}},{"facility":"GSK Investigational Site","city":"Miskolc","zip":"3529","country":"Hungary","geoPoint":{"lat":48.10327,"lon":20.77806}},{"facility":"GSK Investigational Site","city":"Nyíregyháza","zip":"4400","country":"Hungary","geoPoint":{"lat":47.95539,"lon":21.71671}},{"facility":"GSK Investigational Site","city":"Pécs","zip":"7623","country":"Hungary","geoPoint":{"lat":46.07617,"lon":18.22814}},{"facility":"GSK Investigational Site","city":"Székesfehérvár","zip":"8000","country":"Hungary","geoPoint":{"lat":47.18995,"lon":18.41034}},{"facility":"GSK Investigational Site","city":"Szombathely","zip":"9700","country":"Hungary","geoPoint":{"lat":47.23088,"lon":16.62155}},{"facility":"GSK Investigational Site","city":"Törökbálint","zip":"2045","country":"Hungary","geoPoint":{"lat":47.42931,"lon":18.91356}},{"facility":"GSK Investigational Site","city":"Zalaegerszeg-Pozva","zip":"8900","country":"Hungary"},{"facility":"GSK Investigational Site","city":"Bialystok","zip":"15-540","country":"Poland","geoPoint":{"lat":53.13333,"lon":23.16433}},{"facility":"GSK Investigational Site","city":"Bydgoszcz","zip":"85-769","country":"Poland","geoPoint":{"lat":53.1235,"lon":18.00762}},{"facility":"GSK Investigational Site","city":"Gdansk","zip":"80-211","country":"Poland","geoPoint":{"lat":54.35227,"lon":18.64912}},{"facility":"GSK Investigational Site","city":"Krakow","zip":"31-115","country":"Poland","geoPoint":{"lat":50.06143,"lon":19.93658}},{"facility":"GSK Investigational Site","city":"Olsztyn","zip":"10-226","country":"Poland","geoPoint":{"lat":53.78376,"lon":20.49272}},{"facility":"GSK Investigational Site","city":"Olsztyn","zip":"10-357","country":"Poland","geoPoint":{"lat":53.78376,"lon":20.49272}},{"facility":"GSK Investigational Site","city":"Poznan","zip":"60-569","country":"Poland","geoPoint":{"lat":52.40692,"lon":16.92993}},{"facility":"GSK Investigational Site","city":"Kazan'","zip":"420111","country":"Russia","geoPoint":{"lat":55.78874,"lon":49.12214}},{"facility":"GSK Investigational Site","city":"Moscow","zip":"105229","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"GSK Investigational Site","city":"Moscow","zip":"115 478","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"GSK Investigational Site","city":"Moscow","zip":"128128","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"GSK Investigational Site","city":"Moscow","zip":"129 128","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"GSK Investigational Site","city":"Obninsk","zip":"249036","country":"Russia","geoPoint":{"lat":55.10993,"lon":36.61238}},{"facility":"GSK Investigational Site","city":"Orenburg","zip":"460021","country":"Russia","geoPoint":{"lat":51.76712,"lon":55.09883}},{"facility":"GSK Investigational Site","city":"Saint Petersburg","zip":"197022","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"GSK Investigational Site","city":"Saint Petersburg","zip":"197758","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"GSK Investigational Site","city":"Voronezh","zip":"394062","country":"Russia","geoPoint":{"lat":51.66833,"lon":39.19204}},{"facility":"GSK Investigational Site","city":"Banská Bystrica","zip":"975 17","country":"Slovakia","geoPoint":{"lat":48.73947,"lon":19.14932}},{"facility":"GSK Investigational Site","city":"Bratislava","zip":"826 06","country":"Slovakia","geoPoint":{"lat":48.14816,"lon":17.10674}},{"facility":"GSK Investigational Site","city":"Nitra","zip":"949 01","country":"Slovakia","geoPoint":{"lat":48.30763,"lon":18.08453}}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Chemoradiation: Topotecan Plus WBRT","description":"Participants received topotecan 1.1 milligrams per meters squared per day (mg/m2/day), orally followed approximately 2 hours later by whole-brain radiation therapy (WBRT) 3 Gray (Gy)/day to midline over the course of 10 days. After a 2-week washout period, participants completing chemoradiation and willing to participate in the Continuation Phase of the study received oral topotecan 2.3 mg/m2/day for 5 days, every 21 days, as monotherapy provided the baseline hematologic requirements were met. Monotherapy continued until disease progression or discontinuation. Chemoradiation participants choosing not to participate in the Continuation Phase may have received other chemotherapies or best supportive care, as determined by the investigator."},{"id":"FG001","title":"Radiation: WBRT Alone","description":"Participants received WBRT 3 Gy/day for 10 days. Participants may have received other chemotherapies or best supportive care, as determined by the investigator."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"236"},{"groupId":"FG001","numSubjects":"236"}]},{"type":"Ongoing","achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"206"},{"groupId":"FG001","numSubjects":"204"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"30"},{"groupId":"FG001","numSubjects":"32"}]}],"dropWithdraws":[{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"6"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"15"}]},{"type":"Investigator Decision","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"6"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Ongoing","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Chemoradiation: Topotecan Plus WBRT","description":"Participants received topotecan 1.1 milligrams per meters squared per day (mg/m2/day), orally followed approximately 2 hours later by whole-brain radiation therapy (WBRT) 3 Gray (Gy)/day to midline over the course of 10 days. After a 2-week washout period, participants completing chemoradiation and willing to participate in the Continuation Phase of the study received oral topotecan 2.3 mg/m2/day for 5 days, every 21 days, as monotherapy provided the baseline hematologic requirements were met. Monotherapy continued until disease progression or discontinuation. Chemoradiation participants choosing not to participate in the Continuation Phase may have received other chemotherapies or best supportive care, as determined by the investigator."},{"id":"BG001","title":"Radiation: WBRT Alone","description":"Participants received WBRT 3 Gy/day for 10 days. Participants may have received other chemotherapies or best supportive care, as determined by the investigator."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"236"},{"groupId":"BG001","value":"236"},{"groupId":"BG002","value":"472"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"59.4","spread":"8.56"},{"groupId":"BG001","value":"57.8","spread":"8.65"},{"groupId":"BG002","value":"58.6","spread":"8.63"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"84"},{"groupId":"BG001","value":"78"},{"groupId":"BG002","value":"162"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"152"},{"groupId":"BG001","value":"158"},{"groupId":"BG002","value":"310"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"African American/African Heritage (Her.)","categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"4"}]}]},{"title":"Central/South Asian Heritage","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}]},{"title":"Japanese/East Asian Heritage/South East Asian Her.","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"}]}]},{"title":"Native Hawaiian or other Pacific Islander","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}]},{"title":"White","categories":[{"measurements":[{"groupId":"BG000","value":"230"},{"groupId":"BG001","value":"232"},{"groupId":"BG002","value":"462"}]}]},{"title":"Asian & White","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival","description":"Overall survival is defined as the time from randomization until the date of death due to any cause. The date of last contact was used for those participants who had not died or were lost to follow-up. These participants were classified as having been censored.","populationDescription":"Intent-to-Treat (ITT) Population: all randomized participants. Participants were analyzed by the treatment to which they were randomized, even if this differed from the treatment they actually received.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From the time of Randomization until the date of death due to any cause (up to 195 weeks)","groups":[{"id":"OG000","title":"Chemoradiation: Topotecan Plus WBRT","description":"Participants received topotecan 1.1 milligrams per meters squared per day (mg/m2/day), orally followed approximately 2 hours later by whole-brain radiation therapy (WBRT) 3 Gray (Gy)/day to midline over the course of 10 days. After a 2-week washout period, participants completing chemoradiation and willing to participate in the Continuation Phase of the study received oral topotecan 2.3 mg/m2/day for 5 days, every 21 days, as monotherapy provided the baseline hematologic requirements were met. Monotherapy continued until disease progression or discontinuation. Chemoradiation participants choosing not to participate in the Continuation Phase may have received other chemotherapies or best supportive care, as determined by the investigator."},{"id":"OG001","title":"Radiation: WBRT Alone","description":"Participants received WBRT 3 Gy/day for 10 days. Participants may have received other chemotherapies or best supportive care, as determined by the investigator."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"236"},{"groupId":"OG001","value":"236"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0","lowerLimit":"3.4","upperLimit":"4.8"},{"groupId":"OG001","value":"3.6","lowerLimit":"3.0","upperLimit":"4.0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1862","pValueComment":"p-value from a stratified log-rank test is adjusted for Recursive Partitioning Analysis (RPA) class and the number of brain lesions at Screening.","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.88","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.73","ciUpperLimit":"1.07","estimateComment":"The hazard ratio is estimated using a Pike estimator. The hazard ratio from a stratified log-rank test is adjusted for RPA class and the number of brain lesions at Screening."}]},{"type":"SECONDARY","title":"Six-month Survival","description":"Six-month survival is defined as the percentage of participants alive at 6 months following randomization. The date of last contact was used for those participants who had not died or were lost to follow-up. These participants were classified as having been censored.","populationDescription":"ITT Population","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of participants","timeFrame":"Month 6","groups":[{"id":"OG000","title":"Chemoradiation: Topotecan Plus WBRT","description":"Participants received topotecan 1.1 milligrams per meters squared per day (mg/m2/day), orally followed approximately 2 hours later by whole-brain radiation therapy (WBRT) 3 Gray (Gy)/day to midline over the course of 10 days. After a 2-week washout period, participants completing chemoradiation and willing to participate in the Continuation Phase of the study received oral topotecan 2.3 mg/m2/day for 5 days, every 21 days, as monotherapy provided the baseline hematologic requirements were met. Monotherapy continued until disease progression or discontinuation. Chemoradiation participants choosing not to participate in the Continuation Phase may have received other chemotherapies or best supportive care, as determined by the investigator."},{"id":"OG001","title":"Radiation: WBRT Alone","description":"Participants received WBRT 3 Gy/day for 10 days. Participants may have received other chemotherapies or best supportive care, as determined by the investigator."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"236"},{"groupId":"OG001","value":"236"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"28"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a Complete Response (CR) or a Partial Response (PR) (Central Nervous System [CNS]-Radiologic)","description":"The number of participants achieving either a CR or PR, per World Health Organization (WHO) Criteria, in the CNS was assessed. CR is defined as the complete disappearance of all known measurable (Must be accurately measured in \\>=1 dimension) and nonmeasurable disease, without clinical, laboratory, or radiological evidence of recurrence for at least 4 weeks. CR may have been defined in participants with measurable and/or non-measurable disease at Screening. PR is defined as at least a 50% decrease in the sum of the products of the greatest length and perpendicular width of all measurable disease with no clear increase in nonmeasurable disease in participants without measurable disease. In both cases, there must have been no appearance of new disease, and no clinical, laboratory, or radiological evidence of disease progression for at least 4 weeks. Assessment of response was performed by the investigator and was based on unconfirmed responses.","populationDescription":"ITT Population","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"From the time of Randomization until the time of CR or PR (up to 75 weeks)","groups":[{"id":"OG000","title":"Chemoradiation: Topotecan Plus WBRT","description":"Participants received topotecan 1.1 milligrams per meters squared per day (mg/m2/day), orally followed approximately 2 hours later by whole-brain radiation therapy (WBRT) 3 Gray (Gy)/day to midline over the course of 10 days. After a 2-week washout period, participants completing chemoradiation and willing to participate in the Continuation Phase of the study received oral topotecan 2.3 mg/m2/day for 5 days, every 21 days, as monotherapy provided the baseline hematologic requirements were met. Monotherapy continued until disease progression or discontinuation. Chemoradiation participants choosing not to participate in the Continuation Phase may have received other chemotherapies or best supportive care, as determined by the investigator."},{"id":"OG001","title":"Radiation: WBRT Alone","description":"Participants received WBRT 3 Gy/day for 10 days. Participants may have received other chemotherapies or best supportive care, as determined by the investigator."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"236"},{"groupId":"OG001","value":"236"}]}],"classes":[{"title":"Complete response","categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"11"}]}]},{"title":"Partial response","categories":[{"measurements":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"61"}]}]}]},{"type":"SECONDARY","title":"Time to Response (TTR) (CNS-radiologic)","description":"TTR is defined as the time from Randomization until the first documented evidence of CR or PR in the CNS. CR is defined as the complete disappearance of all known measurable (Must be accurately measured in \\>=1 dimension) and nonmeasurable disease, without clinical, laboratory, or radiological evidence of recurrence for at least 4 weeks. CR may have been defined in participants with measurable and/or non-measurable disease at Screening. PR is defined as at least a 50% decrease in the sum of the products of the greatest length and perpendicular width of all measurable disease with no clear increase in nonmeasurable disease in participants without measurable disease. In both cases, there must have been no appearance of new disease, and no clinical, laboratory, or radiological evidence of disease progression for at least 4 weeks. Assessment of response was performed by the investigator and was based on unconfirmed responses.","populationDescription":"ITT Population. Only those participants with a CR, PR, or a missing response were assessed. TTR was analyzed with censoring for extended loss to follow-up to account for two or more missed response assessments before a TTR event. The date of the last adequate CNS assessment before extended loss to follow-up was used for censored participants.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"weeks","timeFrame":"From the time of Randomization until the first documented evidence of CR or PR (up to 75 weeks)","groups":[{"id":"OG000","title":"Chemoradiation: Topotecan Plus WBRT","description":"Participants received topotecan 1.1 milligrams per meters squared per day (mg/m2/day), orally followed approximately 2 hours later by whole-brain radiation therapy (WBRT) 3 Gray (Gy)/day to midline over the course of 10 days. After a 2-week washout period, participants completing chemoradiation and willing to participate in the Continuation Phase of the study received oral topotecan 2.3 mg/m2/day for 5 days, every 21 days, as monotherapy provided the baseline hematologic requirements were met. Monotherapy continued until disease progression or discontinuation. Chemoradiation participants choosing not to participate in the Continuation Phase may have received other chemotherapies or best supportive care, as determined by the investigator."},{"id":"OG001","title":"Radiation: WBRT Alone","description":"Participants received WBRT 3 Gy/day for 10 days. Participants may have received other chemotherapies or best supportive care, as determined by the investigator."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"173"},{"groupId":"OG001","value":"170"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","lowerLimit":"7.7","upperLimit":"8.1"},{"groupId":"OG001","value":"8.1","lowerLimit":"6.0","upperLimit":"8.1"}]}]}]},{"type":"SECONDARY","title":"Time to Progression (TTP) (CNS-radiologic)","description":"TTP is defined as the time from Randomization until the first documented sign of disease progression in the CNS. Progressive disease (PD) is defined as an increase \\>=25% in any measurable lesion or, in participants with non-measurable disease only, an estimation of an increase \\>=25%. In both cases, determination of progression included the appearance of any new lesions, or signification worsening of conditions presumed to be related to malignancy. Participants with clinical or laboratory evidence of possible disease progression were to be evaluated radiologically. TTP was analyzed with censoring for extended loss to follow-up to account for two or more missed assessments before a TTP event. The date of the last adequate CNS assessment before extended loss to follow-up was used for censored participants.","populationDescription":"ITT Population","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"weeks","timeFrame":"From the time of Randomization until the first documented sign of disease progression (up to 75 weeks)","groups":[{"id":"OG000","title":"Chemoradiation: Topotecan Plus WBRT","description":"Participants received topotecan 1.1 milligrams per meters squared per day (mg/m2/day), orally followed approximately 2 hours later by whole-brain radiation therapy (WBRT) 3 Gray (Gy)/day to midline over the course of 10 days. After a 2-week washout period, participants completing chemoradiation and willing to participate in the Continuation Phase of the study received oral topotecan 2.3 mg/m2/day for 5 days, every 21 days, as monotherapy provided the baseline hematologic requirements were met. Monotherapy continued until disease progression or discontinuation. Chemoradiation participants choosing not to participate in the Continuation Phase may have received other chemotherapies or best supportive care, as determined by the investigator."},{"id":"OG001","title":"Radiation: WBRT Alone","description":"Participants received WBRT 3 Gy/day for 10 days. Participants may have received other chemotherapies or best supportive care, as determined by the investigator."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"236"},{"groupId":"OG001","value":"236"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.7","lowerLimit":"8.1","upperLimit":"13.9"},{"groupId":"OG001","value":"9.7","lowerLimit":"8.3","upperLimit":"10.9"}]}]}]},{"type":"SECONDARY","title":"Time to Progression (TTP) (All Sites of Disease-radiologic)","description":"TTP is defined as the time from Randomization until the first documented sign of disease progression in all sites of disease. Progressive disease (PD) is defined as an increase \\>=25% in any measurable lesion or, in participants with non-measurable disease only, an estimation of an increase \\>=25%. In both cases, determination of progression included the appearance of any new lesions, or signification worsening of conditions presumed to be related to malignancy. Participants with clinical or laboratory evidence of possible disease progression were to be evaluated radiologically. TTP was analyzed with censoring for extended loss to follow-up to account for two or more missed assessments before a TTP event. The date of the last adequate CNS assessment before extended loss to follow-up was used for censored participants.","populationDescription":"ITT Population","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"weeks","timeFrame":"From the time of Randomization until the first documented sign of disease progression (up to 75 weeks)","groups":[{"id":"OG000","title":"Chemoradiation: Topotecan Plus WBRT","description":"Participants received topotecan 1.1 milligrams per meters squared per day (mg/m2/day), orally followed approximately 2 hours later by whole-brain radiation therapy (WBRT) 3 Gray (Gy)/day to midline over the course of 10 days. After a 2-week washout period, participants completing chemoradiation and willing to participate in the Continuation Phase of the study received oral topotecan 2.3 mg/m2/day for 5 days, every 21 days, as monotherapy provided the baseline hematologic requirements were met. Monotherapy continued until disease progression or discontinuation. Chemoradiation participants choosing not to participate in the Continuation Phase may have received other chemotherapies or best supportive care, as determined by the investigator."},{"id":"OG001","title":"Radiation: WBRT Alone","description":"Participants received WBRT 3 Gy/day for 10 days. Participants may have received other chemotherapies or best supportive care, as determined by the investigator."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"236"},{"groupId":"OG001","value":"236"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","lowerLimit":"6.7","upperLimit":"8.7"},{"groupId":"OG001","value":"7.7","lowerLimit":"6.1","upperLimit":"8.1"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Ranked Each Individual Indicated Neurological Sign and Symptom as None, Mild, Moderate, or Severe at Months 1 and 3","description":"Neurological signs and symptoms data were derived from a participant-reported diary. The participants were asked to assess the following signs and symptoms on a scale of none, mild, moderate, or severe at Months 1 and 3: headache, problems with balance/coordination (PB/C), leg weakness, arm weakness, loss of feeling/numbness (LofF/N), speech difficulty (SD), confusion, loss of memory (LofM), drowsiness, nausea, vomiting, dizziness, visual problems (VP), seizures, leg/ankle swelling (L/AS), heart burn, difficulty sleeping (DS), tiredness, and appetite/weight gain (A/WG).","populationDescription":"ITT Population. Only those participants who were assessed for the indicated sign and symptom at the indicated time point were analyzed.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Months 1 and 3","groups":[{"id":"OG000","title":"Chemoradiation: Topotecan Plus WBRT","description":"Participants received topotecan 1.1 milligrams per meters squared per day (mg/m2/day), orally followed approximately 2 hours later by whole-brain radiation therapy (WBRT) 3 Gray (Gy)/day to midline over the course of 10 days. After a 2-week washout period, participants completing chemoradiation and willing to participate in the Continuation Phase of the study received oral topotecan 2.3 mg/m2/day for 5 days, every 21 days, as monotherapy provided the baseline hematologic requirements were met. Monotherapy continued until disease progression or discontinuation. Chemoradiation participants choosing not to participate in the Continuation Phase may have received other chemotherapies or best supportive care, as determined by the investigator."},{"id":"OG001","title":"Radiation: WBRT Alone","description":"Participants received WBRT 3 Gy/day for 10 days. Participants may have received other chemotherapies or best supportive care, as determined by the investigator."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"179"},{"groupId":"OG001","value":"189"}]}],"classes":[{"title":"Headache, Month 1, none, n=179, 189","categories":[{"measurements":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"106"}]}]},{"title":"Headache, Month 1, mild, n=179, 189","categories":[{"measurements":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"68"}]}]},{"title":"Headache, Month 1, moderate, 179, 189","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"13"}]}]},{"title":"Headache, Month 1, severe, 179, 189","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"}]}]},{"title":"Headache, Month 3, none, n=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"53"}]}]},{"title":"Headache, Month 3, mild, n=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"41"}]}]},{"title":"Headache, Month 3, moderate, n=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"14"}]}]},{"title":"Headache, Month 3, severe, n=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"}]}]},{"title":"PB/C, Month 1, none, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"79"}]}]},{"title":"PB/C, Month 1, mild, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"71"}]}]},{"title":"PB/C, Month 1, moderate, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"30"}]}]},{"title":"PB/C, Month 1, severe, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"8"}]}]},{"title":"PB/C, Month 3, none, n=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"46"}]}]},{"title":"PB/C, Month 3, mild, n=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"36"}]}]},{"title":"PB/C, Month 3, moderate, n=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"18"}]}]},{"title":"PB/C, Month 3, severe, n=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"11"}]}]},{"title":"Leg weakness, Month 1, none, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"59"}]}]},{"title":"Leg weakness, Month 1, mild, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"72"}]}]},{"title":"Leg weakness, Month 1, moderate, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"41"}]}]},{"title":"Leg weakness, Month 1, severe, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"16"}]}]},{"title":"Leg weakness, Month 3, none, n=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"34"}]}]},{"title":"Leg weakness, Month 3, mild, n=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"37"}]}]},{"title":"Leg weakness, Month 3, moderate, n=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"19"}]}]},{"title":"Leg weakness, Month 3, severe, n=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"21"}]}]},{"title":"Arm weakness, Month 1, none, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"97"}]}]},{"title":"Arm weakness, Month 1, mild, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"60"}]}]},{"title":"Arm weakness, Month 1, moderate, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"18"}]}]},{"title":"Arm weakness, Month 1, severe, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"13"}]}]},{"title":"Arm weakness, Month 3, none, n=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"53"}]}]},{"title":"Arm weakness, Month 3, mild, n=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"34"}]}]},{"title":"Arm weakness, Month 3, molderate, n=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"16"}]}]},{"title":"Arm weakness, Month 3, severe, n=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"8"}]}]},{"title":"LofF/N, Month 1, none, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"11"}]}]},{"title":"LofF/N, Month 1, mild, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"43"}]}]},{"title":"LofF/N, Month 1, moderate, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"25"}]}]},{"title":"LofF/N, Month 1, severe, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"9"}]}]},{"title":"LofF/N, Month 3, none, n=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"66"}]}]},{"title":"LofF/N, Month 3, mild, n=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"27"}]}]},{"title":"LofF/N, Month 3, moderate, n=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"11"}]}]},{"title":"LofF/N, Month 3, severe, n=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"7"}]}]},{"title":"SD, Month 1, none, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"151"},{"groupId":"OG001","value":"137"}]}]},{"title":"SD, Month 1, mild, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"40"}]}]},{"title":"SD, Month 1, moderate, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"9"}]}]},{"title":"SD, Month 1, severe, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"}]}]},{"title":"SD, Month 3, none, n=109, 110","categories":[{"measurements":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"78"}]}]},{"title":"SD, Month 3, mild, n=109, 110","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"22"}]}]},{"title":"SD, Month 3, moderate, n=109, 110","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"8"}]}]},{"title":"SD, Month 3, severe, n=109, 110","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}]},{"title":"Confusion, Month 1, none, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"150"},{"groupId":"OG001","value":"148"}]}]},{"title":"Confusion, Month 1, mild, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"32"}]}]},{"title":"Confusion, Month 1, moderate, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"}]}]},{"title":"Confusion, Month 1, severe, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"}]}]},{"title":"Confusion, Month 3, none, n=109, 110","categories":[{"measurements":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"71"}]}]},{"title":"Confusion, Month 3, mild, n=109, 110","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"29"}]}]},{"title":"Confusion, Month 3, moderate, n=109, 110","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"9"}]}]},{"title":"Confusion, Month 3, severe, n=109, 110","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"LofM, Month 1, none, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"141"}]}]},{"title":"LofM, Month 1, mild, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"41"}]}]},{"title":"LofM, Month 1, moderate, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"5"}]}]},{"title":"LofM, Month 1, severe, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}]},{"title":"LofM, Month 3, none, n=109, 110","categories":[{"measurements":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"78"}]}]},{"title":"LofM, Month 3, mild, n=109, 110","categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"25"}]}]},{"title":"LofM, Month 3, moderate, n=109, 110","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"6"}]}]},{"title":"LofM, Month 3, severe, n=109, 110","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"Drowsiness, Month 1, none, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"90"},{"groupId":"OG001","value":"96"}]}]},{"title":"Drowsiness, Month 1, mild, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"59"}]}]},{"title":"Drowsiness, Month 1, moderate, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"26"}]}]},{"title":"Drowsiness, Month 1, severe, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"7"}]}]},{"title":"Drowsiness, Month 3, none, n=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"44"}]}]},{"title":"Drowsiness, Month 3, mild, n=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"40"}]}]},{"title":"Drowsiness, Month 3, moderate, n=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"15"}]}]},{"title":"Drowsiness, Month 3, severe, n=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"12"}]}]},{"title":"Nausea, Month 1, none, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"125"},{"groupId":"OG001","value":"142"}]}]},{"title":"Nausea, Month 1, mild, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"36"}]}]},{"title":"Nausea, Month 1, moderate, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"10"}]}]},{"title":"Nausea, Month 1, severe, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"0"}]}]},{"title":"Nausea, Month 3, none, n=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"73"}]}]},{"title":"Nausea, Month 3, mild, n=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"29"}]}]},{"title":"Nausea, Month 3, moderate, n=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"6"}]}]},{"title":"Nausea, Month 3, severe, n=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"}]}]},{"title":"Vomiting, Month 1, none, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"153"},{"groupId":"OG001","value":"164"}]}]},{"title":"Vomiting, Month 1, mild, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"19"}]}]},{"title":"Vomiting, Month 1, moderate, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"}]}]},{"title":"Vomiting, Month 1, severe, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}]},{"title":"Vomiting, Month 3, none, n=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"91"}]}]},{"title":"Vomiting, Month 3, mild, n=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"15"}]}]},{"title":"Vomiting, Month 3, moderate, n=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"}]}]},{"title":"Vomiting, Month 3, severe=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}]}]},{"title":"Dizziness, Month 1, none, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"94"}]}]},{"title":"Dizziness, Month 1, mild, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"70"}]}]},{"title":"Dizziness, Month 1, moderate, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"21"}]}]},{"title":"Dizziness, Month 1, severe, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}]},{"title":"Dizziness, Month 3, none, n=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"54"}]}]},{"title":"Dizziness, Month 3, mild, n=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"36"}]}]},{"title":"Dizziness, Month 3, moderate, n=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"14"}]}]},{"title":"Dizziness, Month 3, severe, n=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"7"}]}]},{"title":"VP, Month 1, none, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"103"},{"groupId":"OG001","value":"117"}]}]},{"title":"VP, Month 1, mild, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"53"}]}]},{"title":"VP, Month 1, moderate, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"16"}]}]},{"title":"VP, Month 1, severe, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"}]}]},{"title":"VP, Month 3, none, n=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"72"},{"groupId":"OG001","value":"69"}]}]},{"title":"VP, Month 3, mild, n=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"28"}]}]},{"title":"VP, Month 3, moderate, n=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"10"}]}]},{"title":"VP, Month 3, severe, n=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"}]}]},{"title":"Seizures, Month 1, none, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"173"},{"groupId":"OG001","value":"179"}]}]},{"title":"Seizures, Month 1, mild, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"7"}]}]},{"title":"Seizures, Month 1, moderate, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}]}]},{"title":"Seizures, Month 1, severe, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Seizures, Month 3, none, n=109, 110","categories":[{"measurements":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"102"}]}]},{"title":"Seizures, Month 3, mild, n=109, 110","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"}]}]},{"title":"Seizures, Month 3, moderate, n=109, 110","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"}]}]},{"title":"Seizures, Month 3, severe, n=109, 110","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"L/AS, Month 1, none, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"141"},{"groupId":"OG001","value":"138"}]}]},{"title":"L/AS, Month 1, mild, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"29"}]}]},{"title":"L/AS, Month 1, moderate, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"15"}]}]},{"title":"L/AS, Month 1, severe, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"}]}]},{"title":"L/AS, Month 3, none, n=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"85"}]}]},{"title":"L/AS, Month 3, mild, n=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"19"}]}]},{"title":"L/AS, Month 3, moderate, n=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"}]}]},{"title":"L/AS, Month 3, severe, n=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"Heartburn, Month 1, none, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"151"}]}]},{"title":"Heartburn, Month 1, mild, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"27"}]}]},{"title":"Heartburn, Month 1, moderate, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"9"}]}]},{"title":"Heartburn, Month 1, severe, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}]},{"title":"Heartburn, Month 3, none, n=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"86"}]}]},{"title":"Heartburn, Month 3, mild, n=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"18"}]}]},{"title":"Heartburn, Month 3, moderate, n=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"6"}]}]},{"title":"Heartburn, Month 3, severe, n=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}]},{"title":"DS, Month 1, none, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"112"},{"groupId":"OG001","value":"109"}]}]},{"title":"DS, Month 1, mild, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"48"}]}]},{"title":"DS, Month 1, moderate, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"24"}]}]},{"title":"DS, Month 1, severe, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"7"}]}]},{"title":"DS, Month 3, none, n=109, 110","categories":[{"measurements":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"71"}]}]},{"title":"DS, Month 3, mild, n=109, 110","categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"23"}]}]},{"title":"DS, Month 3, moderate, n=109, 110","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"12"}]}]},{"title":"DS, Month 3, severe, n=109, 110","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"}]}]},{"title":"Tiredness, Month 1, none, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"42"}]}]},{"title":"Tiredness, Month 1, mild, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"85"}]}]},{"title":"Tiredness, Month 1, moderate, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"44"}]}]},{"title":"Tiredness, Month 1, severe, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"17"}]}]},{"title":"Tiredness, Month 3, none, n=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"21"}]}]},{"title":"Tiredness, Month 3, mild, n=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"42"}]}]},{"title":"Tiredness, Month 3, moderate, n=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"32"}]}]},{"title":"Tiredness, Month 3, severe, n=109, 111","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"16"}]}]},{"title":"A/WG, Month 1, none, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"113"}]}]},{"title":"A/WG, Month 1, mild, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"41"}]}]},{"title":"A/WG, Month 1, moderate, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"29"}]}]},{"title":"A/WG, Month 1, severe, n=179, 188","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"5"}]}]},{"title":"A/WG, Month 3, none, n=108, 111","categories":[{"measurements":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"73"}]}]},{"title":"A/WG, Month 3, mild, n=108, 111","categories":[{"measurements":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"23"}]}]},{"title":"A/WG, Month 3, moderate, n=108, 111","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"11"}]}]},{"title":"A/WG, Month 3, severe, n=108, 111","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"4"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Level of Consciousness at Baseline, Month 1, and Month 3","description":"The investigator assessed participants for the neurological sign and symptom of level of consciousness and assigned each participant to one of the following categories: normal; somnolence or sedation not interfering with function (not intefering); somnolence or sedation interfering with function, but not activities of daily living (ADLs) (interfering); obtundation or stupor, difficult to arouse, inteferring with ADLs (obtundation or stupor); coma.","populationDescription":"ITT Population. Only those participants who were assessed at the indicated time point were analyzed. If no data are presented for a particular status at a particular time point, then no participants had that status at that time point.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Baseline, Month 1, and Month 3","groups":[{"id":"OG000","title":"Chemoradiation: Topotecan Plus WBRT","description":"Participants received topotecan 1.1 milligrams per meters squared per day (mg/m2/day), orally followed approximately 2 hours later by whole-brain radiation therapy (WBRT) 3 Gray (Gy)/day to midline over the course of 10 days. After a 2-week washout period, participants completing chemoradiation and willing to participate in the Continuation Phase of the study received oral topotecan 2.3 mg/m2/day for 5 days, every 21 days, as monotherapy provided the baseline hematologic requirements were met. Monotherapy continued until disease progression or discontinuation. Chemoradiation participants choosing not to participate in the Continuation Phase may have received other chemotherapies or best supportive care, as determined by the investigator."},{"id":"OG001","title":"Radiation: WBRT Alone","description":"Participants received WBRT 3 Gy/day for 10 days. Participants may have received other chemotherapies or best supportive care, as determined by the investigator."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"230"},{"groupId":"OG001","value":"228"}]}],"classes":[{"title":"Baseline, normal, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"219"},{"groupId":"OG001","value":"216"}]}]},{"title":"Month 1, normal, n=178, 180","categories":[{"measurements":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"169"}]}]},{"title":"Month 3, normal, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"102"},{"groupId":"OG001","value":"92"}]}]},{"title":"Baseline, not interfering, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"9"}]}]},{"title":"Month 1, not interfering, n=178, 180","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"7"}]}]},{"title":"Month 3, not interfering, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"8"}]}]},{"title":"Baseline, interfering, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}]},{"title":"Month 1, interfering, n=178, 180","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"}]}]},{"title":"Month 3, interfering, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"}]}]},{"title":"Baseline, obtundation and stupor, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Month 1, obtundation and stupor, n=178, 180","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"Month 3, obtundation and stupor, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Headache at Baseline, Month 1, and Month 3","description":"The investigator (per Common Terminology Criteria for Adverse Events \\[CTCAE\\], version 3.0) assessed participants for headache and assigned each participant to one of the following categories: absent, Grade (G) 1, G 2, G 3, G 4, and G 5. Grade refers to the severity of the AE. The CTCAE displays G 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: G 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; G 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental ADL; G 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self care ADL; G 4: life-threatening consequences, urgent intervention indicated; G 5: death related to AE.","populationDescription":"ITT Population. Only those participants who were assessed at the indicated time point were analyzed. If no data are presented for a particular grade at a particular time point, then no participants had an event of that grade at that time point.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Baseline, Month 1, and Month 3","groups":[{"id":"OG000","title":"Chemoradiation: Topotecan Plus WBRT","description":"Participants received topotecan 1.1 milligrams per meters squared per day (mg/m2/day), orally followed approximately 2 hours later by whole-brain radiation therapy (WBRT) 3 Gray (Gy)/day to midline over the course of 10 days. After a 2-week washout period, participants completing chemoradiation and willing to participate in the Continuation Phase of the study received oral topotecan 2.3 mg/m2/day for 5 days, every 21 days, as monotherapy provided the baseline hematologic requirements were met. Monotherapy continued until disease progression or discontinuation. Chemoradiation participants choosing not to participate in the Continuation Phase may have received other chemotherapies or best supportive care, as determined by the investigator."},{"id":"OG001","title":"Radiation: WBRT Alone","description":"Participants received WBRT 3 Gy/day for 10 days. Participants may have received other chemotherapies or best supportive care, as determined by the investigator."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"230"},{"groupId":"OG001","value":"228"}]}],"classes":[{"title":"Baseline, absent, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"141"},{"groupId":"OG001","value":"146"}]}]},{"title":"Month 1, absent, n=178, 180","categories":[{"measurements":[{"groupId":"OG000","value":"126"},{"groupId":"OG001","value":"127"}]}]},{"title":"Month 3, absent, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"74"}]}]},{"title":"Baseline, Grade 1, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"55"}]}]},{"title":"Month 1, Grade 1, n=178, 180","categories":[{"measurements":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"38"}]}]},{"title":"Month 3, Grade 1, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"23"}]}]},{"title":"Baseline, Grade 2, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"23"}]}]},{"title":"Month 1, Grade 2, n=178, 180","categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"14"}]}]},{"title":"Month 3, Grade 2, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"10"}]}]},{"title":"Baseline, Grade 3, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"}]}]},{"title":"Month 1, Grade 3, n=178, 180","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Dizziness/Lightheadedness at Baseline, Month 1, and Month 3","description":"The investigator (per CTCAE, version 3.0) assessed participants for dizziness/lightheadedness and assigned each participant to one of the following categories: absent, G 1, G 2, G 3, G 4, and G 5. Grade refers to the severity of the AE. The CTCAE displays G 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: G 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; G 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental ADL; G 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self care ADL; G 4: life-threatening consequences, urgent intervention indicated; G 5: death related to AE.","populationDescription":"ITT Population. Only those participants who were assessed at the indicated time point were analyzed. If no data are presented for a particular grade at a particular time point, then no participants had an event of that grade at that time point.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Baseline, Month 1, and Month 3","groups":[{"id":"OG000","title":"Chemoradiation: Topotecan Plus WBRT","description":"Participants received topotecan 1.1 milligrams per meters squared per day (mg/m2/day), orally followed approximately 2 hours later by whole-brain radiation therapy (WBRT) 3 Gray (Gy)/day to midline over the course of 10 days. After a 2-week washout period, participants completing chemoradiation and willing to participate in the Continuation Phase of the study received oral topotecan 2.3 mg/m2/day for 5 days, every 21 days, as monotherapy provided the baseline hematologic requirements were met. Monotherapy continued until disease progression or discontinuation. Chemoradiation participants choosing not to participate in the Continuation Phase may have received other chemotherapies or best supportive care, as determined by the investigator."},{"id":"OG001","title":"Radiation: WBRT Alone","description":"Participants received WBRT 3 Gy/day for 10 days. Participants may have received other chemotherapies or best supportive care, as determined by the investigator."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"230"},{"groupId":"OG001","value":"228"}]}],"classes":[{"title":"Baseline, absent, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"160"},{"groupId":"OG001","value":"151"}]}]},{"title":"Month 1, absent, n=178, 180","categories":[{"measurements":[{"groupId":"OG000","value":"124"},{"groupId":"OG001","value":"128"}]}]},{"title":"Month 3, absent, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"76"}]}]},{"title":"Baseline, Grade 1, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"47"}]}]},{"title":"Month 1, Grade 1, n=178, 180","categories":[{"measurements":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"36"}]}]},{"title":"Month 3, Grade 1, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"20"}]}]},{"title":"Baseline, Grade 2, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"26"}]}]},{"title":"Month 1, Grade 2, n=178, 180","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"14"}]}]},{"title":"Month 3, Grade 2, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"9"}]}]},{"title":"Baseline, Grade 3, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"}]}]},{"title":"Month 1, Grade 3, n=178, 180","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"}]}]},{"title":"Month 3, Grade 3, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Vertigo at Baseline, Month 1, and Month 3","description":"The investigator (per CTCAE, version 3.0) assessed participants for vertigo and assigned each participant to one of the following categories: absent, G 1, G 2, G 3, G 4, and G 5. Grade refers to the severity of the AE. The CTCAE displays G 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: G 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; G 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental ADL; G 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self care ADL; G 4: life-threatening consequences, urgent intervention indicated; G 5: death related to AE.","populationDescription":"ITT Population. Only those participants who were assessed at the indicated time point were analyzed. If no data are presented for a particular grade at a particular time point, then no participants had an event of that grade at that time point.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Baseline, Month 1, and Month 3","groups":[{"id":"OG000","title":"Chemoradiation: Topotecan Plus WBRT","description":"Participants received topotecan 1.1 milligrams per meters squared per day (mg/m2/day), orally followed approximately 2 hours later by whole-brain radiation therapy (WBRT) 3 Gray (Gy)/day to midline over the course of 10 days. After a 2-week washout period, participants completing chemoradiation and willing to participate in the Continuation Phase of the study received oral topotecan 2.3 mg/m2/day for 5 days, every 21 days, as monotherapy provided the baseline hematologic requirements were met. Monotherapy continued until disease progression or discontinuation. Chemoradiation participants choosing not to participate in the Continuation Phase may have received other chemotherapies or best supportive care, as determined by the investigator."},{"id":"OG001","title":"Radiation: WBRT Alone","description":"Participants received WBRT 3 Gy/day for 10 days. Participants may have received other chemotherapies or best supportive care, as determined by the investigator."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"230"},{"groupId":"OG001","value":"228"}]}],"classes":[{"title":"Baseline, absent, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"180"},{"groupId":"OG001","value":"173"}]}]},{"title":"Month 1, absent, n=178, 180","categories":[{"measurements":[{"groupId":"OG000","value":"148"},{"groupId":"OG001","value":"150"}]}]},{"title":"Month 3, absent, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"90"},{"groupId":"OG001","value":"86"}]}]},{"title":"Baseline, Grade 1, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"30"}]}]},{"title":"Month 1, Grade 1, n=178, 180","categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"19"}]}]},{"title":"Month 3, Grade 1, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"13"}]}]},{"title":"Baseline, Grade 2, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"22"}]}]},{"title":"Month 1, Grade 2, n=178, 180","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"9"}]}]},{"title":"Month 3, Grade 2, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"6"}]}]},{"title":"Baseline, Grade 3, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"}]}]},{"title":"Month 1, Grade 3, n=178, 180","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"}]}]},{"title":"Month 3, Grade 3, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}]}]},{"title":"Month 1, Grade 4, n=178, 180","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Nausea/Vomiting at Baseline, Month 1, and Month 3","description":"The investigator (per CTCAE, version 3.0) assessed participants for nausea/vomiting and assigned each participant to one of the following categories: absent, G 1, G 2, G 3, G 4, and G 5. Grade refers to the severity of the AE. The CTCAE displays G 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: G 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; G 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental ADL; G 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self care ADL; G 4: life-threatening consequences, urgent intervention indicated; G 5: death related to AE.","populationDescription":"ITT Population. Only those participants who were assessed at the indicated time point were analyzed. If no data are presented for a particular grade at a particular time point, then no participants had an event of that grade at that time point.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Baseline, Month 1, and Month 3","groups":[{"id":"OG000","title":"Chemoradiation: Topotecan Plus WBRT","description":"Participants received topotecan 1.1 milligrams per meters squared per day (mg/m2/day), orally followed approximately 2 hours later by whole-brain radiation therapy (WBRT) 3 Gray (Gy)/day to midline over the course of 10 days. After a 2-week washout period, participants completing chemoradiation and willing to participate in the Continuation Phase of the study received oral topotecan 2.3 mg/m2/day for 5 days, every 21 days, as monotherapy provided the baseline hematologic requirements were met. Monotherapy continued until disease progression or discontinuation. Chemoradiation participants choosing not to participate in the Continuation Phase may have received other chemotherapies or best supportive care, as determined by the investigator."},{"id":"OG001","title":"Radiation: WBRT Alone","description":"Participants received WBRT 3 Gy/day for 10 days. Participants may have received other chemotherapies or best supportive care, as determined by the investigator."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"230"},{"groupId":"OG001","value":"228"}]}],"classes":[{"title":"Baseline, absent, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"203"},{"groupId":"OG001","value":"192"}]}]},{"title":"Month 1, absent, n=178, 180","categories":[{"measurements":[{"groupId":"OG000","value":"151"},{"groupId":"OG001","value":"162"}]}]},{"title":"Month 3, absent, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"93"}]}]},{"title":"Baseline, Grade 1, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"22"}]}]},{"title":"Month 1, Grade 1, n=178, 180","categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"15"}]}]},{"title":"Month 3, Grade 1, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"11"}]}]},{"title":"Baseline, Grade 2, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"10"}]}]},{"title":"Month 1, Grade 2, n=178, 180","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"}]}]},{"title":"Month 3, Grade 2, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"}]}]},{"title":"Baseline, Grade 3, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"}]}]},{"title":"Month 1, Grade 3, n=178, 180","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Month 3, Grade 5, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Visual Problem at Baseline, Month 1, and Month 3","description":"The investigator (per CTCAE, version 3.0) assessed participants for visual problem and assigned each participant to one of the following categories: absent, G 1, G 2, G 3, G 4, and G 5. Grade refers to the severity of the AE. The CTCAE displays G 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: G 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; G 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental ADL; G 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self care ADL; G 4: life-threatening consequences, urgent intervention indicated; G 5: death related to AE.","populationDescription":"ITT Population. Only those participants who were assessed at the indicated time point were analyzed. If no data are presented for a particular grade at a particular time point, then no participants had an event of that grade at that time point.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Baseline, Month 1, and Month 3","groups":[{"id":"OG000","title":"Chemoradiation: Topotecan Plus WBRT","description":"Participants received topotecan 1.1 milligrams per meters squared per day (mg/m2/day), orally followed approximately 2 hours later by whole-brain radiation therapy (WBRT) 3 Gray (Gy)/day to midline over the course of 10 days. After a 2-week washout period, participants completing chemoradiation and willing to participate in the Continuation Phase of the study received oral topotecan 2.3 mg/m2/day for 5 days, every 21 days, as monotherapy provided the baseline hematologic requirements were met. Monotherapy continued until disease progression or discontinuation. Chemoradiation participants choosing not to participate in the Continuation Phase may have received other chemotherapies or best supportive care, as determined by the investigator."},{"id":"OG001","title":"Radiation: WBRT Alone","description":"Participants received WBRT 3 Gy/day for 10 days. Participants may have received other chemotherapies or best supportive care, as determined by the investigator."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"230"},{"groupId":"OG001","value":"228"}]}],"classes":[{"title":"Baseline, absent, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"181"},{"groupId":"OG001","value":"189"}]}]},{"title":"Month 1, absent, n=178, 180","categories":[{"measurements":[{"groupId":"OG000","value":"148"},{"groupId":"OG001","value":"154"}]}]},{"title":"Month 3, absent, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"93"}]}]},{"title":"Baseline, Grade 1, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"25"}]}]},{"title":"Month 1, Grade 1, n=178, 180","categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"19"}]}]},{"title":"Month 3, Grade 1, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"10"}]}]},{"title":"Baseline, Grade 2, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"13"}]}]},{"title":"Month 1, Grade 2, n=178, 180","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"6"}]}]},{"title":"Month 3, Grade 2, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"}]}]},{"title":"Baseline, Grade 3, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"1"}]}]},{"title":"Month 1, Grade 3, n=178, 180","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}]},{"title":"Month 3, Grade 3, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Baseline, Grade 4, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"Month 1, Grade 4, n=178, 180","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Seizure at Baseline, Month 1, and Month 3","description":"The investigator (per CTCAE, version 3.0) assessed participants for seizure and assigned each participant to one of the following categories: absent, G 1, G 2, G 3, G 4, and G 5. Grade refers to the severity of the AE. The CTCAE displays G 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: G 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; G 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental ADL; G 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self care ADL; G 4: life-threatening consequences, urgent intervention indicated; G 5: death related to AE.","populationDescription":"ITT Population. Only those participants who were assessed at the indicated time point were analyzed. If no data are presented for a particular grade at a particular time point, then no participants had an event of that grade at that time point.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Baseline, Month 1, and Month 3","groups":[{"id":"OG000","title":"Chemoradiation: Topotecan Plus WBRT","description":"Participants received topotecan 1.1 milligrams per meters squared per day (mg/m2/day), orally followed approximately 2 hours later by whole-brain radiation therapy (WBRT) 3 Gray (Gy)/day to midline over the course of 10 days. After a 2-week washout period, participants completing chemoradiation and willing to participate in the Continuation Phase of the study received oral topotecan 2.3 mg/m2/day for 5 days, every 21 days, as monotherapy provided the baseline hematologic requirements were met. Monotherapy continued until disease progression or discontinuation. Chemoradiation participants choosing not to participate in the Continuation Phase may have received other chemotherapies or best supportive care, as determined by the investigator."},{"id":"OG001","title":"Radiation: WBRT Alone","description":"Participants received WBRT 3 Gy/day for 10 days. Participants may have received other chemotherapies or best supportive care, as determined by the investigator."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"230"},{"groupId":"OG001","value":"228"}]}],"classes":[{"title":"Baseline, absent, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"218"},{"groupId":"OG001","value":"216"}]}]},{"title":"Month 1, absent, n=178, 180","categories":[{"measurements":[{"groupId":"OG000","value":"175"},{"groupId":"OG001","value":"178"}]}]},{"title":"Month 3, absent, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"101"}]}]},{"title":"Baseline, Grade 1, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"6"}]}]},{"title":"Month 1, Grade 1, n=178, 180","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}]},{"title":"Month 3, Grade 1, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"}]}]},{"title":"Baseline, Grade 2, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"}]}]},{"title":"Month 1, Grade 2, n=178, 180","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"Month 3, Grade 2, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]},{"title":"Baseline, Grade 3, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Baseline, Grade 4, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With the Indicated Investigator Assessment for the Neurological Sign and Symptom of Other Neurological Symptoms at Baseline, Month 1, and Month 3","description":"The investigator (per CTCAE, version 3.0) assessed participants for other neurological symptoms and assigned each participant to one of the following categories: absent, G 1, G 2, G 3, G 4, and G 5. Grade refers to the severity of the AE. The CTCAE displays G 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: G 1: mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; G 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental ADL; G 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self care ADL; G 4: life-threatening consequences, urgent intervention indicated; G 5: death related to AE.","populationDescription":"ITT Population. Only those participants who were assessed at the indicated time point were analyzed. If no data are presented for a particular grade at a particular time point, then no participants had an event of that grade at that time point.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Baseline, Month 1, and Month 3","groups":[{"id":"OG000","title":"Chemoradiation: Topotecan Plus WBRT","description":"Participants received topotecan 1.1 milligrams per meters squared per day (mg/m2/day), orally followed approximately 2 hours later by whole-brain radiation therapy (WBRT) 3 Gray (Gy)/day to midline over the course of 10 days. After a 2-week washout period, participants completing chemoradiation and willing to participate in the Continuation Phase of the study received oral topotecan 2.3 mg/m2/day for 5 days, every 21 days, as monotherapy provided the baseline hematologic requirements were met. Monotherapy continued until disease progression or discontinuation. Chemoradiation participants choosing not to participate in the Continuation Phase may have received other chemotherapies or best supportive care, as determined by the investigator."},{"id":"OG001","title":"Radiation: WBRT Alone","description":"Participants received WBRT 3 Gy/day for 10 days. Participants may have received other chemotherapies or best supportive care, as determined by the investigator."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"229"},{"groupId":"OG001","value":"228"}]}],"classes":[{"title":"Baseline, absent, n=229, 228","categories":[{"measurements":[{"groupId":"OG000","value":"219"},{"groupId":"OG001","value":"214"}]}]},{"title":"Month 1, absent, n=177, 180","categories":[{"measurements":[{"groupId":"OG000","value":"165"},{"groupId":"OG001","value":"171"}]}]},{"title":"Month 3, absent, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"101"}]}]},{"title":"Baseline, Grade 1, n=229, 228","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"5"}]}]},{"title":"Month 1, Grade 1, n=177, 180","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"}]}]},{"title":"Month 3, Grade 1, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"}]}]},{"title":"Baseline, Grade 2, n=229, 228","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"8"}]}]},{"title":"Month 1, Grade 2, n=177, 180","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"1"}]}]},{"title":"Month 3, Grade 2, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"}]}]},{"title":"Baseline, Grade 3, n=229, 228","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"Month 1, Grade 3, n=177, 180","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}]},{"title":"Month 1, Grade 4, n=177, 180","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Month 3, Grade 5, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With the Indicated Investigator Assessment of Cranial Nerves II-XII at Baseline, Month 1, and Month 3","description":"The investigator assessed participants' status of cranial nerves II-XII and assigned each participant to one of the following categories: normal; present, not interfering with ADLs; present, interfering with ADLs; life threatening, disabling.","populationDescription":"ITT Population. Only those participants who were assessed at the indicated time point were analyzed. If no data are presented for a particular status at a particular time point, then no participants had that status at that time point.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Baseline, Month 1, and Month 3","groups":[{"id":"OG000","title":"Chemoradiation: Topotecan Plus WBRT","description":"Participants received topotecan 1.1 milligrams per meters squared per day (mg/m2/day), orally followed approximately 2 hours later by whole-brain radiation therapy (WBRT) 3 Gray (Gy)/day to midline over the course of 10 days. After a 2-week washout period, participants completing chemoradiation and willing to participate in the Continuation Phase of the study received oral topotecan 2.3 mg/m2/day for 5 days, every 21 days, as monotherapy provided the baseline hematologic requirements were met. Monotherapy continued until disease progression or discontinuation. Chemoradiation participants choosing not to participate in the Continuation Phase may have received other chemotherapies or best supportive care, as determined by the investigator."},{"id":"OG001","title":"Radiation: WBRT Alone","description":"Participants received WBRT 3 Gy/day for 10 days. Participants may have received other chemotherapies or best supportive care, as determined by the investigator."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"229"},{"groupId":"OG001","value":"225"}]}],"classes":[{"title":"Baseline, normal, n=229, 225","categories":[{"measurements":[{"groupId":"OG000","value":"218"},{"groupId":"OG001","value":"211"}]}]},{"title":"Month 1, normal, n=177, 179","categories":[{"measurements":[{"groupId":"OG000","value":"172"},{"groupId":"OG001","value":"169"}]}]},{"title":"Month 3, normal, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"102"}]}]},{"title":"Baseline, present, not interfering, n=229, 225","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"10"}]}]},{"title":"Month 1, present, not interfering, n=177, 179","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"6"}]}]},{"title":"Month 3, present, not interfering, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"}]}]},{"title":"Baseline, present, interfering, n=229, 225","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"}]}]},{"title":"Month 1, present, interfering, n=177, 179","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"}]}]},{"title":"Month 3, present, interfering, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With the Indicated Investigator Assessment of Language (Dysphasia or Aphasia) at Baseline, Month 1, and Month 3","description":"The investigator assessed participants' status of language (dysphasia or aphasia) and assigned each participant to one of the following categories: absent; awareness of receptive or expressive aphasia, not impairing ability to communicate (not impaired); receptive or expressive dysphasia, impairing ability to communicate (impaired); inability to communicate (unable).","populationDescription":"ITT Population. Only those participants who were assessed at the indicated time point were analyzed. If no data are presented for a particular status at a particular time point, then no participants had that status at that time point.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Baseline, Month 1, and Month 3","groups":[{"id":"OG000","title":"Chemoradiation: Topotecan Plus WBRT","description":"Participants received topotecan 1.1 milligrams per meters squared per day (mg/m2/day), orally followed approximately 2 hours later by whole-brain radiation therapy (WBRT) 3 Gray (Gy)/day to midline over the course of 10 days. After a 2-week washout period, participants completing chemoradiation and willing to participate in the Continuation Phase of the study received oral topotecan 2.3 mg/m2/day for 5 days, every 21 days, as monotherapy provided the baseline hematologic requirements were met. Monotherapy continued until disease progression or discontinuation. Chemoradiation participants choosing not to participate in the Continuation Phase may have received other chemotherapies or best supportive care, as determined by the investigator."},{"id":"OG001","title":"Radiation: WBRT Alone","description":"Participants received WBRT 3 Gy/day for 10 days. Participants may have received other chemotherapies or best supportive care, as determined by the investigator."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"230"},{"groupId":"OG001","value":"228"}]}],"classes":[{"title":"Baseline, absent, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"211"},{"groupId":"OG001","value":"215"}]}]},{"title":"Month 1, absent, n=178, 180","categories":[{"measurements":[{"groupId":"OG000","value":"169"},{"groupId":"OG001","value":"173"}]}]},{"title":"Month 3, absent, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"105"},{"groupId":"OG001","value":"98"}]}]},{"title":"Baseline, not impaired, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"10"}]}]},{"title":"Month 1, not impaired, n=178, 180","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"}]}]},{"title":"Month 3, not impaired, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"7"}]}]},{"title":"Baseline, impaired, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"}]}]},{"title":"Month 1, impaired, n=178, 180","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"}]}]},{"title":"Month 3, impaired, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Baseline, unable, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Month 3, unable, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With the Indicated Investigator Assessment of Strength (Right Upper Extremity) at Baseline, Month 1, and Month 3","description":"The investigator assessed participants' status of strength (right upper extremity) and assigned each participant to one of the following categories: normal; Grade 1, asymptomatic with weakness on physical examination; Grade 2, symptomatic and interfering with function, but not interfering with ADLs; Grade 3, symptomatic and interfering with ADLs; Grade 4: bedridden or disabling.","populationDescription":"ITT Population. Only those participants who were assessed at the indicated time point were analyzed. If no data are presented for a particular status at a particular time point, then no participants had that status at that time point.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Baseline, Month 1, and Month 3","groups":[{"id":"OG000","title":"Chemoradiation: Topotecan Plus WBRT","description":"Participants received topotecan 1.1 milligrams per meters squared per day (mg/m2/day), orally followed approximately 2 hours later by whole-brain radiation therapy (WBRT) 3 Gray (Gy)/day to midline over the course of 10 days. After a 2-week washout period, participants completing chemoradiation and willing to participate in the Continuation Phase of the study received oral topotecan 2.3 mg/m2/day for 5 days, every 21 days, as monotherapy provided the baseline hematologic requirements were met. Monotherapy continued until disease progression or discontinuation. Chemoradiation participants choosing not to participate in the Continuation Phase may have received other chemotherapies or best supportive care, as determined by the investigator."},{"id":"OG001","title":"Radiation: WBRT Alone","description":"Participants received WBRT 3 Gy/day for 10 days. Participants may have received other chemotherapies or best supportive care, as determined by the investigator."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"230"},{"groupId":"OG001","value":"228"}]}],"classes":[{"title":"Baseline, normal, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"203"},{"groupId":"OG001","value":"195"}]}]},{"title":"Month 1, normal, n=178, 179","categories":[{"measurements":[{"groupId":"OG000","value":"153"},{"groupId":"OG001","value":"159"}]}]},{"title":"Month 3, normal, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"89"}]}]},{"title":"Baseline, Grade 1, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"16"}]}]},{"title":"Month 1, Grade 1, n=178, 179","categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"12"}]}]},{"title":"Month 3, Grade 1, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"}]}]},{"title":"Baseline, Grade 2, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"12"}]}]},{"title":"Month 1, Grade 2, n=178, 179","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"}]}]},{"title":"Month 3, Grade 2, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"}]}]},{"title":"Baseline, Grade 3, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"5"}]}]},{"title":"Month 1, Grade 3, n=178, 179","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"}]}]},{"title":"Month 3, Grade 3, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"}]}]},{"title":"Baseline, Grade 4, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}]},{"title":"Month 1, Grade 4, n=178, 179","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With the Indicated Investigator Assessment of Strength (Left Upper Extremity) at Baseline, Month 1, and Month 3","description":"The investigator assessed participants' status of strength (left upper extremity) and assigned each participant to one of the following categories: normal; Grade 1, asymptomatic with weakness on physical examination; Grade 2, symptomatic and interfering with function, but not interfering with ADLs; Grade 3, symptomatic and interfering with ADLs; Grade 4: bedridden or disabling.","populationDescription":"ITT Population. Only those participants who were assessed at the indicated time point were analyzed. If no data are presented for a particular status at a particular time point, then no participants had that status at that time point.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Baseline, Month 1, and Month 3","groups":[{"id":"OG000","title":"Chemoradiation: Topotecan Plus WBRT","description":"Participants received topotecan 1.1 milligrams per meters squared per day (mg/m2/day), orally followed approximately 2 hours later by whole-brain radiation therapy (WBRT) 3 Gray (Gy)/day to midline over the course of 10 days. After a 2-week washout period, participants completing chemoradiation and willing to participate in the Continuation Phase of the study received oral topotecan 2.3 mg/m2/day for 5 days, every 21 days, as monotherapy provided the baseline hematologic requirements were met. Monotherapy continued until disease progression or discontinuation. Chemoradiation participants choosing not to participate in the Continuation Phase may have received other chemotherapies or best supportive care, as determined by the investigator."},{"id":"OG001","title":"Radiation: WBRT Alone","description":"Participants received WBRT 3 Gy/day for 10 days. Participants may have received other chemotherapies or best supportive care, as determined by the investigator."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"230"},{"groupId":"OG001","value":"228"}]}],"classes":[{"title":"Baseline, normal, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"202"}]}]},{"title":"Month 1, normal, n=178, 179","categories":[{"measurements":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"157"}]}]},{"title":"Month 3, normal, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"90"},{"groupId":"OG001","value":"86"}]}]},{"title":"Baseline, Grade 1, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"13"}]}]},{"title":"Month 1, Grade 1, n=178, 179","categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"13"}]}]},{"title":"Month 3, Grade 1, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"11"}]}]},{"title":"Baseline, Grade 2, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"8"}]}]},{"title":"Month 1, Grade 2, n=178, 179","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"5"}]}]},{"title":"Month 3, Grade 2, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"}]}]},{"title":"Baseline, Grade 3, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"4"}]}]},{"title":"Month 1, Grade 3, n=178, 179","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"}]}]},{"title":"Month 3, Grade 3, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"}]}]},{"title":"Baseline, Grade 4, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Month 1, Grade 4, n=178, 179","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}]},{"title":"Month 3, Grade 4, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With the Indicated Investigator Assessment of Strength (Right Lower Extremity) at Baseline, Month 1, and Month 3","description":"The investigator assessed participants' status of strength (right lower extremity) and assigned each participant to one of the following categories: normal; Grade 1, asymptomatic with weakness on physical examination; Grade 2, symptomatic and interfering with function, but not interfering with ADLs; Grade 3, symptomatic and interfering with ADLs; Grade 4: bedridden or disabling.","populationDescription":"ITT Population. Only those participants who were assessed at the indicated time point were analyzed. If no data are presented for a particular status at a particular time point, then no participants had that status at that time point.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Baseline, Month 1, and Month 3","groups":[{"id":"OG000","title":"Chemoradiation: Topotecan Plus WBRT","description":"Participants received topotecan 1.1 milligrams per meters squared per day (mg/m2/day), orally followed approximately 2 hours later by whole-brain radiation therapy (WBRT) 3 Gray (Gy)/day to midline over the course of 10 days. After a 2-week washout period, participants completing chemoradiation and willing to participate in the Continuation Phase of the study received oral topotecan 2.3 mg/m2/day for 5 days, every 21 days, as monotherapy provided the baseline hematologic requirements were met. Monotherapy continued until disease progression or discontinuation. Chemoradiation participants choosing not to participate in the Continuation Phase may have received other chemotherapies or best supportive care, as determined by the investigator."},{"id":"OG001","title":"Radiation: WBRT Alone","description":"Participants received WBRT 3 Gy/day for 10 days. Participants may have received other chemotherapies or best supportive care, as determined by the investigator."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"230"},{"groupId":"OG001","value":"228"}]}],"classes":[{"title":"Baseline, normal, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"196"},{"groupId":"OG001","value":"189"}]}]},{"title":"Month 1, normal, n=178, 180","categories":[{"measurements":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"145"}]}]},{"title":"Month 3, normal, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"80"}]}]},{"title":"Baseline, Grade 1, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"19"}]}]},{"title":"Month 1, Grade 1, n=178, 180","categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"15"}]}]},{"title":"Month 3, Grade 1, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"11"}]}]},{"title":"Baseline, Grade 2, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"16"}]}]},{"title":"Month 1, Grade 2, n=178, 180","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"19"}]}]},{"title":"Month 3, Grade 2, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"11"}]}]},{"title":"Baseline, Grade 3, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"}]}]},{"title":"Month 1, Grade 3, n=178, 180","categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"0"}]}]},{"title":"Month 3, Grade 3, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"}]}]},{"title":"Baseline, Grade 4, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"Month 1, Grade 4, n=178, 180","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"}]}]},{"title":"Month 3, Grade 4, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With the Indicated Investigator Assessment of Strength (Left Lower Extremity) at Baseline, Month 1, and Month 3","description":"The investigator assessed participants' status of strength (left lower extremity) and assigned each participant to one of the following categories: normal; Grade 1, asymptomatic with weakness on physical examination; Grade 2, symptomatic and interfering with function, but not interfering with ADLs; Grade 3, symptomatic and interfering with ADLs; Grade 4: bedridden or disabling.","populationDescription":"ITT Population. Only those participants who were assessed at the indicated time point were analyzed. If no data are presented for a particular status at a particular time point, then no participants had that status at that time point.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Baseline, Month 1, and Month 3","groups":[{"id":"OG000","title":"Chemoradiation: Topotecan Plus WBRT","description":"Participants received topotecan 1.1 milligrams per meters squared per day (mg/m2/day), orally followed approximately 2 hours later by whole-brain radiation therapy (WBRT) 3 Gray (Gy)/day to midline over the course of 10 days. After a 2-week washout period, participants completing chemoradiation and willing to participate in the Continuation Phase of the study received oral topotecan 2.3 mg/m2/day for 5 days, every 21 days, as monotherapy provided the baseline hematologic requirements were met. Monotherapy continued until disease progression or discontinuation. Chemoradiation participants choosing not to participate in the Continuation Phase may have received other chemotherapies or best supportive care, as determined by the investigator."},{"id":"OG001","title":"Radiation: WBRT Alone","description":"Participants received WBRT 3 Gy/day for 10 days. Participants may have received other chemotherapies or best supportive care, as determined by the investigator."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"230"},{"groupId":"OG001","value":"228"}]}],"classes":[{"title":"Baseline, normal, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"190"}]}]},{"title":"Month 1, normal, n=178, 179","categories":[{"measurements":[{"groupId":"OG000","value":"128"},{"groupId":"OG001","value":"143"}]}]},{"title":"Month 3, normal, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"73"}]}]},{"title":"Baseline, Grade 1, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"18"}]}]},{"title":"Month 1, Grade 1, n=178, 179","categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"13"}]}]},{"title":"Month 3, Grade 1, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"11"}]}]},{"title":"Baseline, Grade 2, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"15"}]}]},{"title":"Month 1, Grade 2, n=178, 179","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"17"}]}]},{"title":"Month 3, Grade 2, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"14"}]}]},{"title":"Baseline, Grade 3, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"}]}]},{"title":"Month 1, Grade 3, n=178, 179","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"4"}]}]},{"title":"Month 3, Grade 3, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"}]}]},{"title":"Baseline, Grade 4, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}]}]},{"title":"Month 1, Grade 4, n=178, 179","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"}]}]},{"title":"Month 3, Grade 4, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With the Indicated Investigator Assessment of Sensation at Baseline, Month 1, and Month 3","description":"The investigator assessed participants' status of sensation and assigned each participant to one of the following categories: normal; loss of deep tendon reflexes or paresthesia, but not interfering with function (not interfering with function); objective sensory loss or paresthesia interfering with function, but not interfering with ADLs (interfering with function); sensory loss or paresthesia interfering with ADLs (intefering with ADLs); permanent sensory loss that interferes with function (permanent sensory loss).","populationDescription":"ITT Population. Only those participants who were assessed at the indicated time point were analyzed. If no data are presented for a particular status at a particular time point, then no participants had that status at that time point.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Baseline, Month 1, and Month 3","groups":[{"id":"OG000","title":"Chemoradiation: Topotecan Plus WBRT","description":"Participants received topotecan 1.1 milligrams per meters squared per day (mg/m2/day), orally followed approximately 2 hours later by whole-brain radiation therapy (WBRT) 3 Gray (Gy)/day to midline over the course of 10 days. After a 2-week washout period, participants completing chemoradiation and willing to participate in the Continuation Phase of the study received oral topotecan 2.3 mg/m2/day for 5 days, every 21 days, as monotherapy provided the baseline hematologic requirements were met. Monotherapy continued until disease progression or discontinuation. Chemoradiation participants choosing not to participate in the Continuation Phase may have received other chemotherapies or best supportive care, as determined by the investigator."},{"id":"OG001","title":"Radiation: WBRT Alone","description":"Participants received WBRT 3 Gy/day for 10 days. Participants may have received other chemotherapies or best supportive care, as determined by the investigator."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"230"},{"groupId":"OG001","value":"228"}]}],"classes":[{"title":"Baseline (BL), normal, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"192"}]}]},{"title":"Month (M) 1, normal, n=178, 180","categories":[{"measurements":[{"groupId":"OG000","value":"144"},{"groupId":"OG001","value":"159"}]}]},{"title":"Month 3, normal, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"94"}]}]},{"title":"BL, not interfering with function, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"26"}]}]},{"title":"M 1, not interfering with function, n=178, 180","categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"15"}]}]},{"title":"M 3, not interfering with function, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"9"}]}]},{"title":"BL, interfering with function, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"}]}]},{"title":"M 1, interfering with function, n=178, 180","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"4"}]}]},{"title":"M 3, interfering with function, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}]},{"title":"Baseline, interfering with ADLs, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"}]}]},{"title":"Month 1, interfering with ADLs, n=178, 180","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"}]}]},{"title":"Month 3, interfering with ADLs, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}]},{"title":"Baseline, permanent sensory loss, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With the Indicated Investigator Assessment of Ataxia (Right Upper Extremity: Finger to Nose Testing) at Baseline, Month 1, and Month 3","description":"The investigator assessed participants' status of ataxia (right upper extremity: finger to nose testing) and assigned each participant to one of the following categories: normal; Grade 1, asymptomatic but abnormal on physical examination, and not interfering with function; Grade 2, mild symptoms interfering with function, but not interfering with ADLs; Grade 3, moderate symptoms interfering with ADLs; Grade 4, bedridden or disabling.","populationDescription":"ITT Population. Only those participants who were assessed at the indicated time point were analyzed. If no data are presented for a particular status at a particular time point, then no participants had that status at that time point.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Baseline, Month 1, and Month 3","groups":[{"id":"OG000","title":"Chemoradiation: Topotecan Plus WBRT","description":"Participants received topotecan 1.1 milligrams per meters squared per day (mg/m2/day), orally followed approximately 2 hours later by whole-brain radiation therapy (WBRT) 3 Gray (Gy)/day to midline over the course of 10 days. After a 2-week washout period, participants completing chemoradiation and willing to participate in the Continuation Phase of the study received oral topotecan 2.3 mg/m2/day for 5 days, every 21 days, as monotherapy provided the baseline hematologic requirements were met. Monotherapy continued until disease progression or discontinuation. Chemoradiation participants choosing not to participate in the Continuation Phase may have received other chemotherapies or best supportive care, as determined by the investigator."},{"id":"OG001","title":"Radiation: WBRT Alone","description":"Participants received WBRT 3 Gy/day for 10 days. Participants may have received other chemotherapies or best supportive care, as determined by the investigator."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"229"},{"groupId":"OG001","value":"228"}]}],"classes":[{"title":"Baseline, normal, n=229, 228","categories":[{"measurements":[{"groupId":"OG000","value":"206"},{"groupId":"OG001","value":"198"}]}]},{"title":"Month 1, normal, 178, 179","categories":[{"measurements":[{"groupId":"OG000","value":"166"},{"groupId":"OG001","value":"166"}]}]},{"title":"Month 3, normal, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"103"},{"groupId":"OG001","value":"95"}]}]},{"title":"Baseline, Grade 1, n=229, 228","categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"17"}]}]},{"title":"Month 1, Grade 1, 178, 179","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"6"}]}]},{"title":"Month 3, Grade 1, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"}]}]},{"title":"Baseline, Grade 2, n=229, 228","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"12"}]}]},{"title":"Month 1, Grade 2, 178, 179","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"}]}]},{"title":"Month 3, Grade 2, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5"}]}]},{"title":"Baseline, Grade 3, n=229, 228","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"}]}]},{"title":"Month 3, Grade 3, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Baseline, Grade 4, n=229, 228","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"Month 1, Grade 4, 178, 179","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}]},{"title":"Month 3, Grade 4, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With the Indicated Investigator Assessment of Ataxia (Left Upper Extremity: Finger to Nose Testing) at Baseline, Month 1, and Month 3","description":"The investigator assessed participants' status of ataxia (left upper extremity: finger to nose testing) and assigned each participant to one of the following categories: normal; Grade 1, asymptomatic but abnormal on physical examination, and not interfering with function; Grade 2, mild symptoms interfering with function, but not interfering with ADLs; Grade 3, moderate symptoms interfering with ADLs; Grade 4, bedridden or disabling.","populationDescription":"ITT Population. Only those participants who were assessed at the indicated time point were analyzed. If no data are presented for a particular status at a particular time point, then no participants had that status at that time point.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Baseline, Month 1, and Month 3","groups":[{"id":"OG000","title":"Chemoradiation: Topotecan Plus WBRT","description":"Participants received topotecan 1.1 milligrams per meters squared per day (mg/m2/day), orally followed approximately 2 hours later by whole-brain radiation therapy (WBRT) 3 Gray (Gy)/day to midline over the course of 10 days. After a 2-week washout period, participants completing chemoradiation and willing to participate in the Continuation Phase of the study received oral topotecan 2.3 mg/m2/day for 5 days, every 21 days, as monotherapy provided the baseline hematologic requirements were met. Monotherapy continued until disease progression or discontinuation. Chemoradiation participants choosing not to participate in the Continuation Phase may have received other chemotherapies or best supportive care, as determined by the investigator."},{"id":"OG001","title":"Radiation: WBRT Alone","description":"Participants received WBRT 3 Gy/day for 10 days. Participants may have received other chemotherapies or best supportive care, as determined by the investigator."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"230"},{"groupId":"OG001","value":"227"}]}],"classes":[{"title":"Baseline, normal, n=230, 227","categories":[{"measurements":[{"groupId":"OG000","value":"199"},{"groupId":"OG001","value":"201"}]}]},{"title":"Month 1, normal, n=178, 178","categories":[{"measurements":[{"groupId":"OG000","value":"156"},{"groupId":"OG001","value":"162"}]}]},{"title":"Month 3, normal, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"97"},{"groupId":"OG001","value":"94"}]}]},{"title":"Baseline, Grade 1, n=230, 227","categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"13"}]}]},{"title":"Month 1, Grade 1, n=178, 178","categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"9"}]}]},{"title":"Month 3, Grade 1, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"6"}]}]},{"title":"Baseline, Grade 2, n=230, 227","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"7"}]}]},{"title":"Month 1, Grade 2, n=178, 178","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"}]}]},{"title":"Month 3, Grade 2, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"}]}]},{"title":"Baseline, Grade 3, n=230, 227","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"4"}]}]},{"title":"Month 1, Grade 3, n=178, 178","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}]}]},{"title":"Month 3, Grade 3, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Baseline, Grade 4, n=230, 227","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]},{"title":"Month 1, Grade 4, n=178, 178","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}]},{"title":"Month 3, Grade 4, n=109, 107","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With the Indicated Investigator Assessment of Ataxia (Gait) at Baseline, Month 1, and Month 3","description":"The investigator assessed participants' status of ataxia (gait) and assigned each participant to one of the following categories: normal; Grade 1, asymptomatic but abnormal on physical examination, and not interfering with function; Grade 2, mild symptoms interfering with function, but not interfering with ADLs; Grade 3, moderate symptoms interfering with ADLs; Grade 4, bedridden or disabling.","populationDescription":"ITT Population. Only those participants who were assessed at the indicated time point were analyzed. If no data are presented for a particular status at a particular time point, then no participants had that status at that time point.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Baseline, Month 1, and Month 3","groups":[{"id":"OG000","title":"Chemoradiation: Topotecan Plus WBRT","description":"Participants received topotecan 1.1 milligrams per meters squared per day (mg/m2/day), orally followed approximately 2 hours later by whole-brain radiation therapy (WBRT) 3 Gray (Gy)/day to midline over the course of 10 days. After a 2-week washout period, participants completing chemoradiation and willing to participate in the Continuation Phase of the study received oral topotecan 2.3 mg/m2/day for 5 days, every 21 days, as monotherapy provided the baseline hematologic requirements were met. Monotherapy continued until disease progression or discontinuation. Chemoradiation participants choosing not to participate in the Continuation Phase may have received other chemotherapies or best supportive care, as determined by the investigator."},{"id":"OG001","title":"Radiation: WBRT Alone","description":"Participants received WBRT 3 Gy/day for 10 days. Participants may have received other chemotherapies or best supportive care, as determined by the investigator."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"230"},{"groupId":"OG001","value":"227"}]}],"classes":[{"title":"Baseline, normal, n=230, 227","categories":[{"measurements":[{"groupId":"OG000","value":"172"},{"groupId":"OG001","value":"178"}]}]},{"title":"Month 1, normal, n=178, 179","categories":[{"measurements":[{"groupId":"OG000","value":"138"},{"groupId":"OG001","value":"147"}]}]},{"title":"Month 3, normal, n=108, 107","categories":[{"measurements":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"76"}]}]},{"title":"Baseline, Grade 1, n=230, 227","categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"22"}]}]},{"title":"Month 1, Grade 1, n=178, 179","categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"13"}]}]},{"title":"Month 3, Grade 1, n=108, 107","categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"10"}]}]},{"title":"Baseline, Grade 2, n=230, 227","categories":[{"measurements":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"20"}]}]},{"title":"Month 1, Grade 2, n=178, 179","categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"14"}]}]},{"title":"Month 3, Grade 2, n=108, 107","categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"12"}]}]},{"title":"Baseline, Grade 3, n=230, 227","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"}]}]},{"title":"Month 1, Grade 3, n=178, 179","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"3"}]}]},{"title":"Month 3, Grade 3, n=108, 107","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"}]}]},{"title":"Baseline, Grade 4, n=230, 227","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}]},{"title":"Month 1, Grade 4, n=178, 179","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"}]}]},{"title":"Month 3, Grade 4, n=108, 107","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With the Indicated Investigator Assessment of Ataxia (Balance) at Baseline, Month 1, and Month 3","description":"The investigator assessed participants' status of ataxia (balance) and assigned each participant to one of the following categories: normal; Grade 1, asymptomatic but abnormal on physical examination, and not interfering with function; Grade 2, mild symptoms interfering with function, but not interfering with ADLs; Grade 3, moderate symptoms interfering with ADLs; Grade 4, bedridden or disabling.","populationDescription":"ITT Population. Only those participants who were assessed at the indicated time point were analyzed. If no data are presented for a particular status at a particular time point, then no participants had that status at that time point.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Baseline, Month 1, and Month 3","groups":[{"id":"OG000","title":"Chemoradiation: Topotecan Plus WBRT","description":"Participants received topotecan 1.1 milligrams per meters squared per day (mg/m2/day), orally followed approximately 2 hours later by whole-brain radiation therapy (WBRT) 3 Gray (Gy)/day to midline over the course of 10 days. After a 2-week washout period, participants completing chemoradiation and willing to participate in the Continuation Phase of the study received oral topotecan 2.3 mg/m2/day for 5 days, every 21 days, as monotherapy provided the baseline hematologic requirements were met. Monotherapy continued until disease progression or discontinuation. Chemoradiation participants choosing not to participate in the Continuation Phase may have received other chemotherapies or best supportive care, as determined by the investigator."},{"id":"OG001","title":"Radiation: WBRT Alone","description":"Participants received WBRT 3 Gy/day for 10 days. Participants may have received other chemotherapies or best supportive care, as determined by the investigator."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"230"},{"groupId":"OG001","value":"228"}]}],"classes":[{"title":"Baseline, normal, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"153"},{"groupId":"OG001","value":"152"}]}]},{"title":"Month 1, normal, n=178, 178","categories":[{"measurements":[{"groupId":"OG000","value":"131"},{"groupId":"OG001","value":"128"}]}]},{"title":"Month 3, normal, n=108, 107","categories":[{"measurements":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"75"}]}]},{"title":"Baseline, Grade 1, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"44"}]}]},{"title":"Month 1, Grade 1, n=178, 178","categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"28"}]}]},{"title":"Month 3, Grade 1, n=108, 107","categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"13"}]}]},{"title":"Baseline, Grade 2, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"23"}]}]},{"title":"Month 1, Grade 2, n=178, 178","categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"16"}]}]},{"title":"Month 3, Grade 2, n=108, 107","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"9"}]}]},{"title":"Baseline, Grade 3, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"7"}]}]},{"title":"Month 1, Grade 3, n=178, 178","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"5"}]}]},{"title":"Month 3, Grade 3, n=108, 107","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"}]}]},{"title":"Baseline, Grade 4, n=230, 228","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"}]}]},{"title":"Month 1, Grade 4, n=178, 178","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"}]}]},{"title":"Month 3, Grade 4, n=108, 107","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Any Adverse Event (AE; Both Serious and Non-serious) or Serious Adverse Event (SAE)","description":"An AE is defined as any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life threatening; requires hospitalization or prolongation of existing hospitalization; results in disability/incapacity; is a congenital anomaly/birth defect. For a list of all SAEs and AEs, see the SAE/AE module of this results summary.","populationDescription":"Modified ITT Population: all randomized participants who received at least one dose of randomized therapy. Participants were analyzed by the actual treatment received, even if this differed from the treatment to which they were randomized.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"From Randomization until the last clinic visit associated with the study, up until 35 days after the start of the last course of treatment (up to 75 weeks)","groups":[{"id":"OG000","title":"Chemoradiation: Topotecan Plus WBRT","description":"Participants received topotecan 1.1 milligrams per meters squared per day (mg/m2/day), orally followed approximately 2 hours later by whole-brain radiation therapy (WBRT) 3 Gray (Gy)/day to midline over the course of 10 days. After a 2-week washout period, participants completing chemoradiation and willing to participate in the Continuation Phase of the study received oral topotecan 2.3 mg/m2/day for 5 days, every 21 days, as monotherapy provided the baseline hematologic requirements were met. Monotherapy continued until disease progression or discontinuation. Chemoradiation participants choosing not to participate in the Continuation Phase may have received other chemotherapies or best supportive care, as determined by the investigator."},{"id":"OG001","title":"Radiation: WBRT Alone","description":"Participants received WBRT 3 Gy/day for 10 days. Participants may have received other chemotherapies or best supportive care, as determined by the investigator."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"235"},{"groupId":"OG001","value":"233"}]}],"classes":[{"title":"AE","categories":[{"measurements":[{"groupId":"OG000","value":"204"},{"groupId":"OG001","value":"148"}]}]},{"title":"SAE","categories":[{"measurements":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"43"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With the Indicated Worst-case Change From Baseline in the Indicated Chemistry Parameters With Respect to the Normal Range","description":"The worst-case change from Baseline in chemistry parameters was measured as decrease to low (DTL), change to normal or no change (CTN/NC), or increase to high (ITH). The worst-case change value could have been measured at any point during the on-therapy period. Participants are counted twice if the participant \"Decreased to Low\" and \"Increased to High\" during the on-therapy period.","populationDescription":"Modified ITT Population. Only those participants with available laboratory values (indicated by the \"n\" in the category titles) were analyzed. Different participants may have been analyzed for different parameters; therefore, the overall number of participants analyzed reflects everyone in the Modified ITT Population.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"From Randomization until the last clinic visit associated with the study, up until 35 days after the start of the last course of treatment (up to 75 weeks)","groups":[{"id":"OG000","title":"Chemoradiation: Topotecan Plus WBRT","description":"Participants received topotecan 1.1 milligrams per meters squared per day (mg/m2/day), orally followed approximately 2 hours later by whole-brain radiation therapy (WBRT) 3 Gray (Gy)/day to midline over the course of 10 days. After a 2-week washout period, participants completing chemoradiation and willing to participate in the Continuation Phase of the study received oral topotecan 2.3 mg/m2/day for 5 days, every 21 days, as monotherapy provided the baseline hematologic requirements were met. Monotherapy continued until disease progression or discontinuation. Chemoradiation participants choosing not to participate in the Continuation Phase may have received other chemotherapies or best supportive care, as determined by the investigator."},{"id":"OG001","title":"Radiation: WBRT Alone","description":"Participants received WBRT 3 Gy/day for 10 days. Participants may have received other chemotherapies or best supportive care, as determined by the investigator."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"235"},{"groupId":"OG001","value":"233"}]}],"classes":[{"title":"Chloride, DTL, n=169, 171","categories":[{"measurements":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"21"}]}]},{"title":"Chloride, CTN/NC, n=169, 171","categories":[{"measurements":[{"groupId":"OG000","value":"116"},{"groupId":"OG001","value":"144"}]}]},{"title":"Chloride, ITH, n=169, 171","categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"6"}]}]},{"title":"Creatinine clearance, DTL, n=159, 145","categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"9"}]}]},{"title":"Creatinine clearance, CTN/NC, n=159, 145","categories":[{"measurements":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"134"}]}]},{"title":"Creatinine clearance, ITH, n=159, 145","categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"2"}]}]},{"title":"Lactate dehydrogenase, DTL, n=169, 168","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"1"}]}]},{"title":"Lactate dehydrogenase, CTN/NC, n=169, 168","categories":[{"measurements":[{"groupId":"OG000","value":"117"},{"groupId":"OG001","value":"127"}]}]},{"title":"Lactate dehydrogenase, ITH, n=169, 168","categories":[{"measurements":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"40"}]}]},{"title":"Total protein, DTL, n=171, 175","categories":[{"measurements":[{"groupId":"OG000","value":"48"},{"groupId":"OG001","value":"36"}]}]},{"title":"Total protein, CTN/NC, n=171, 175","categories":[{"measurements":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"137"}]}]},{"title":"Total protein, ITH, n=171, 175","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"}]}]},{"title":"Urea/blood urea nitrogen, DTL, n=178, 179","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"4"}]}]},{"title":"Urea/blood urea nitrogen, CTN/NC, n=178, 179","categories":[{"measurements":[{"groupId":"OG000","value":"139"},{"groupId":"OG001","value":"152"}]}]},{"title":"Urea/blood urea nitrogen, ITH, n=178, 179","categories":[{"measurements":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"24"}]}]},{"title":"Uric acid, DTL, n=159, 152","categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"12"}]}]},{"title":"Uric acid, CTN/NC, n=159, 152","categories":[{"measurements":[{"groupId":"OG000","value":"125"},{"groupId":"OG001","value":"134"}]}]},{"title":"Uric acid, ITH, n=159, 152","categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"6"}]}]},{"title":"Basophils, DTL, n=215, 211","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"1"}]}]},{"title":"Basophils, CTN/NC, n=215, 211","categories":[{"measurements":[{"groupId":"OG000","value":"186"},{"groupId":"OG001","value":"200"}]}]},{"title":"Basophils, ITH, n=215, 211","categories":[{"measurements":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"10"}]}]},{"title":"Eosinophils, DTL, n=214, 211","categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"12"}]}]},{"title":"Eosinophils, CTN/NC, n=214, 211","categories":[{"measurements":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"191"}]}]},{"title":"Eosinophils, ITH, n=214, 211","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"8"}]}]},{"title":"Hematocrit, DTL, n=215, 212","categories":[{"measurements":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"38"}]}]},{"title":"Hematocrit, CTN/NC, n=215, 212","categories":[{"measurements":[{"groupId":"OG000","value":"117"},{"groupId":"OG001","value":"169"}]}]},{"title":"Hematocrit, ITH, n=215, 212","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"6"}]}]},{"title":"Monocytes, DTL, n=216, 212","categories":[{"measurements":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"17"}]}]},{"title":"Monocytes, CTN/NC, n=216, 212","categories":[{"measurements":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"161"}]}]},{"title":"Monocytes, ITH, n=216, 212","categories":[{"measurements":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"37"}]}]},{"title":"Red Blood Cell Count, DTL, n=216, 212","categories":[{"measurements":[{"groupId":"OG000","value":"103"},{"groupId":"OG001","value":"38"}]}]},{"title":"Red Blood Cell Count, CTN/NC, n=216, 212","categories":[{"measurements":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"171"}]}]},{"title":"Red Blood Cell Count, ITH, n=216, 212","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"}]}]}]},{"type":"SECONDARY","title":"Lesion Assessment and Measurement","description":"Lesions were assessed per WHO criteria. For lesion assessment data, see the outcome measure entitled \"Number of participants with a complete response (CR) or a partial response (PR) (central nervous system \\[CNS\\]-radiologic).\"","reportingStatus":"POSTED","timeFrame":"From the time of Randomization until the time of CR or PR (up to 75 weeks)","groups":[{"id":"OG000","title":"Chemoradiation: Topotecan Plus WBRT","description":"Participants received topotecan 1.1 milligrams per meters squared per day (mg/m2/day), orally followed approximately 2 hours later by whole-brain radiation therapy (WBRT) 3 Gray (Gy)/day to midline over the course of 10 days. After a 2-week washout period, participants completing chemoradiation and willing to participate in the Continuation Phase of the study received oral topotecan 2.3 mg/m2/day for 5 days, every 21 days, as monotherapy provided the baseline hematologic requirements were met. Monotherapy continued until disease progression or discontinuation. Chemoradiation participants choosing not to participate in the Continuation Phase may have received other chemotherapies or best supportive care, as determined by the investigator."},{"id":"OG001","title":"Radiation: WBRT Alone","description":"Participants received WBRT 3 Gy/day for 10 days. Participants may have received other chemotherapies or best supportive care, as determined by the investigator."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"type":"SECONDARY","title":"Brain Symptoms","description":"Brain symptoms were assessed as the number of participants with neurological signs and symptoms. For brain symptom data, see the outcome measures entitled \"Number of participants with the indicated investigator assessment for the neurological sign and symptom of X at Baseline, Month 1, and Month 3.\"","reportingStatus":"POSTED","timeFrame":"Baseline, Month 1, and Month 3","groups":[{"id":"OG000","title":"Chemoradiation: Topotecan Plus WBRT","description":"Participants received topotecan 1.1 milligrams per meters squared per day (mg/m2/day), orally followed approximately 2 hours later by whole-brain radiation therapy (WBRT) 3 Gray (Gy)/day to midline over the course of 10 days. After a 2-week washout period, participants completing chemoradiation and willing to participate in the Continuation Phase of the study received oral topotecan 2.3 mg/m2/day for 5 days, every 21 days, as monotherapy provided the baseline hematologic requirements were met. Monotherapy continued until disease progression or discontinuation. Chemoradiation participants choosing not to participate in the Continuation Phase may have received other chemotherapies or best supportive care, as determined by the investigator."},{"id":"OG001","title":"Radiation: WBRT Alone","description":"Participants received WBRT 3 Gy/day for 10 days. Participants may have received other chemotherapies or best supportive care, as determined by the investigator."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"type":"SECONDARY","title":"Number of Participants Who Died or Progressed","description":"Disease-related events were measured as the number of participants who died or progressed. Progressive disease (PD) is defined as an increase \\>=25% in any measurable lesion or, in participants with non-measurable disease only, an estimation of an increase \\>=25%. In both cases, determination of progression included the appearance of any new lesions, or signification worsening of conditions presumed to be related to malignancy. Participants with clinical or laboratory evidence of possible disease progression were to be evaluated radiologically. Data were analyzed with censoring for extended loss to follow-up to account for two or more missed assessments before an event. The date of the last adequate CNS assessment before extended loss to follow-up was used for censored participants.","populationDescription":"mITT Population","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"From Randomization until the last clinic visit associated with the study, up until 35 days after the start of the last course of treatment (up to 75 weeks)","groups":[{"id":"OG000","title":"Chemoradiation: Topotecan Plus WBRT","description":"Participants received topotecan 1.1 milligrams per meters squared per day (mg/m2/day), orally followed approximately 2 hours later by whole-brain radiation therapy (WBRT) 3 Gray (Gy)/day to midline over the course of 10 days. After a 2-week washout period, participants completing chemoradiation and willing to participate in the Continuation Phase of the study received oral topotecan 2.3 mg/m2/day for 5 days, every 21 days, as monotherapy provided the baseline hematologic requirements were met. Monotherapy continued until disease progression or discontinuation. Chemoradiation participants choosing not to participate in the Continuation Phase may have received other chemotherapies or best supportive care, as determined by the investigator."},{"id":"OG001","title":"Radiation: WBRT Alone","description":"Participants received WBRT 3 Gy/day for 10 days. Participants may have received other chemotherapies or best supportive care, as determined by the investigator."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"235"},{"groupId":"OG001","value":"233"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"179"},{"groupId":"OG001","value":"161"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","description":"Serious adverse events (SAEs) and non-serious AEs were collected in members of the Modified Intent-to-Treat Population, comprised of all randomized participants (par.) who received at least one dose of randomized therapy. Par. were analyzed by the actual treatment received, even if it differed from the treatment to which they were randomized.","eventGroups":[{"id":"EG000","title":"Chemoradiation: Topotecan Plus WBRT","description":"Participants received topotecan 1.1 milligrams per meters squared per day (mg/m2/day), orally followed approximately 2 hours later by whole-brain radiation therapy (WBRT) 3 Gray (Gy)/day to midline over the course of 10 days. After a 2-week washout period, participants completing chemoradiation and willing to participate in the Continuation Phase of the study received oral topotecan 2.3 mg/m2/day for 5 days, every 21 days, as monotherapy provided the baseline hematologic requirements were met. Monotherapy continued until disease progression or discontinuation. Chemoradiation participants choosing not to participate in the Continuation Phase may have received other chemotherapies or best supportive care, as determined by the investigator.","seriousNumAffected":96,"seriousNumAtRisk":235,"otherNumAffected":192,"otherNumAtRisk":235},{"id":"EG001","title":"Radiation: WBRT Alone","description":"Participants received WBRT 3 Gy/day for 10 days. Participants may have received other chemotherapies or best supportive care, as determined by the investigator.","seriousNumAffected":43,"seriousNumAtRisk":233,"otherNumAffected":139,"otherNumAtRisk":233}],"seriousEvents":[{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":22,"numAtRisk":235},{"groupId":"EG001","numAffected":2,"numAtRisk":233}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":22,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":235},{"groupId":"EG001","numAffected":6,"numAtRisk":233}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":235},{"groupId":"EG001","numAffected":3,"numAtRisk":233}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Pancytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":4,"numAtRisk":233}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Dyspnoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Brain oedema","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Disease progression","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":235},{"groupId":"EG001","numAffected":2,"numAtRisk":233}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":3,"numAtRisk":233}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":2,"numAtRisk":233}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Accidental overdose","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Cardiac failure acute","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":2,"numAtRisk":233}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Non-small cell lung cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Overdose","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Performance status decreased","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Pericarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Pulmonary haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":2,"numAtRisk":233}]},{"term":"Small intestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Adrenal insufficiency","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Agranulocytosis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Arterial thrombosis limb","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Bronchial obstruction","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Cardiopulmonary failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Convulsion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Coronary artery insufficiency","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Encephalopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Face injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Femoral neck fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Grand mal convulsion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Hydrocephalus","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Hypernatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Inappropriate antidiuretic hormone secretion","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Intestinal perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Jugular vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Lobar pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Lung abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Lung infiltration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Lymphopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Malnutrition","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Mental status changes","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Myocardial ischaemia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Oesophageal stenosis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Oropharyngeal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Oropharyngitis fungal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Orthostatic hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Paraplegia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Peridiverticular abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Pleurisy","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Radiation pneumonitis","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Radiculopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Stevens-Johnson syndrome","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Superior vena cava syndrome","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Urinary retention","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Venous thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]}],"otherEvents":[{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":64,"numAtRisk":235},{"groupId":"EG001","numAffected":30,"numAtRisk":233}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":37,"numAtRisk":235},{"groupId":"EG001","numAffected":24,"numAtRisk":233}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":235},{"groupId":"EG001","numAffected":8,"numAtRisk":233}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":235},{"groupId":"EG001","numAffected":10,"numAtRisk":233}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":235},{"groupId":"EG001","numAffected":10,"numAtRisk":233}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":235},{"groupId":"EG001","numAffected":6,"numAtRisk":233}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":3,"numAtRisk":233}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":3,"numAtRisk":233}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":2,"numAtRisk":233}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Flatulence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Mouth ulceration","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Rectal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Abdominal discomfort","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Aphthous stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Ascites","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Breath odour","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Faecal incontinence","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Faeces discoloured","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Gingival pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Glossodynia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Haematochezia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Haemorrhoids","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Hyperchlorhydria","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Oesophageal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Oral pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Retching","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":39,"numAtRisk":235},{"groupId":"EG001","numAffected":37,"numAtRisk":233}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":29,"numAtRisk":235},{"groupId":"EG001","numAffected":19,"numAtRisk":233}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":235},{"groupId":"EG001","numAffected":15,"numAtRisk":233}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":235},{"groupId":"EG001","numAffected":5,"numAtRisk":233}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Gait disturbance","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":4,"numAtRisk":233}]},{"term":"Face oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":3,"numAtRisk":233}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":3,"numAtRisk":233}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":2,"numAtRisk":233}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Spinal pain","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Chest discomfort","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Early satiety","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Gravitational oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Hyperthermia","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Influenza like illness","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Local swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Localised oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Mucosal erosion","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":27,"numAtRisk":235},{"groupId":"EG001","numAffected":28,"numAtRisk":233}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":27,"numAtRisk":235},{"groupId":"EG001","numAffected":19,"numAtRisk":233}]},{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":235},{"groupId":"EG001","numAffected":14,"numAtRisk":233}]},{"term":"Hypoaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":235},{"groupId":"EG001","numAffected":11,"numAtRisk":233}]},{"term":"Ataxia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":235},{"groupId":"EG001","numAffected":6,"numAtRisk":233}]},{"term":"Coordination abnormal","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":235},{"groupId":"EG001","numAffected":4,"numAtRisk":233}]},{"term":"Tremor","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":235},{"groupId":"EG001","numAffected":4,"numAtRisk":233}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":235},{"groupId":"EG001","numAffected":4,"numAtRisk":233}]},{"term":"Amnesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":6,"numAtRisk":233}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":235},{"groupId":"EG001","numAffected":2,"numAtRisk":233}]},{"term":"Aphasia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":6,"numAtRisk":233}]},{"term":"Balance disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":7,"numAtRisk":233}]},{"term":"Convulsion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Epilepsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":3,"numAtRisk":233}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":2,"numAtRisk":233}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":2,"numAtRisk":233}]},{"term":"Speech disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":3,"numAtRisk":233}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Brain oedema","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Convulsions local","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Hemiparesis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":2,"numAtRisk":233}]},{"term":"Hemiplegia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Loss of consciousness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Memory impairment","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Psychomotor hyperactivity","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":2,"numAtRisk":233}]},{"term":"Ageusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Alcoholic seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Burning sensation","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Cognitive disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Dysarthria","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Facial paresis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Hypersomnia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Hypotonia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Mental impairment","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Monoplegia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Neuritis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Paresis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Partial seizures","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Peripheral motor neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Polyneuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Sciatica","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Visual field defect","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":31,"numAtRisk":235},{"groupId":"EG001","numAffected":20,"numAtRisk":233}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":26,"numAtRisk":235},{"groupId":"EG001","numAffected":17,"numAtRisk":233}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":235},{"groupId":"EG001","numAffected":2,"numAtRisk":233}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":235},{"groupId":"EG001","numAffected":7,"numAtRisk":233}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":235},{"groupId":"EG001","numAffected":3,"numAtRisk":233}]},{"term":"Hiccups","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":235},{"groupId":"EG001","numAffected":2,"numAtRisk":233}]},{"term":"Dyspnoea exertional","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":3,"numAtRisk":233}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":2,"numAtRisk":233}]},{"term":"Dysphonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Lung infiltration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":2,"numAtRisk":233}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Upper-airway cough syndrome","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Wheezing","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Bronchitis chronic","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Hydrothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Increased upper airway secretion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Laryngeal inflammation","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Pharyngeal inflammation","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Pulmonary hypertension","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Rales","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Respiratory tract congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":29,"numAtRisk":235},{"groupId":"EG001","numAffected":22,"numAtRisk":233}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":235},{"groupId":"EG001","numAffected":6,"numAtRisk":233}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":235},{"groupId":"EG001","numAffected":6,"numAtRisk":233}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":235},{"groupId":"EG001","numAffected":4,"numAtRisk":233}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":235},{"groupId":"EG001","numAffected":2,"numAtRisk":233}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":2,"numAtRisk":233}]},{"term":"Joint swelling","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":2,"numAtRisk":233}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Extremity contracture","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Groin pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Muscle atrophy","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":28,"numAtRisk":235},{"groupId":"EG001","numAffected":17,"numAtRisk":233}]},{"term":"Increased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":235},{"groupId":"EG001","numAffected":6,"numAtRisk":233}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":235},{"groupId":"EG001","numAffected":3,"numAtRisk":233}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":235},{"groupId":"EG001","numAffected":3,"numAtRisk":233}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":4,"numAtRisk":233}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Cachexia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":2,"numAtRisk":233}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Malnutrition","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Polydipsia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":235},{"groupId":"EG001","numAffected":4,"numAtRisk":233}]},{"term":"Oral candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":235},{"groupId":"EG001","numAffected":2,"numAtRisk":233}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":235},{"groupId":"EG001","numAffected":4,"numAtRisk":233}]},{"term":"Candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":235},{"groupId":"EG001","numAffected":2,"numAtRisk":233}]},{"term":"Oral fungal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":3,"numAtRisk":233}]},{"term":"Oropharyngitis fungal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":3,"numAtRisk":233}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":2,"numAtRisk":233}]},{"term":"Rhinitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":2,"numAtRisk":233}]},{"term":"Cystitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":2,"numAtRisk":233}]},{"term":"Herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":2,"numAtRisk":233}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Oesophageal candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Oral herpes","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Oropharyngeal candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Anal fungal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Fungal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Fungal oesophagitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Furuncle","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Herpes simplex","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Mastoiditis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Orchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Otitis media","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Rash pustular","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Soft tissue infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Tonsillitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Tracheobronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Vaginal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Vulvovaginal mycotic infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":235},{"groupId":"EG001","numAffected":19,"numAtRisk":233}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":235},{"groupId":"EG001","numAffected":11,"numAtRisk":233}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":2,"numAtRisk":233}]},{"term":"Mood altered","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":2,"numAtRisk":233}]},{"term":"Nervousness","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":2,"numAtRisk":233}]},{"term":"Delusion","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Depressed mood","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Disorientation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Initial insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Mental disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Sleep disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Staring","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":21,"numAtRisk":235},{"groupId":"EG001","numAffected":17,"numAtRisk":233}]},{"term":"Erythema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":3,"numAtRisk":233}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":2,"numAtRisk":233}]},{"term":"Swelling face","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":2,"numAtRisk":233}]},{"term":"Acne","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Ecchymosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Night sweats","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Skin disorder","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":2,"numAtRisk":233}]},{"term":"Skin ulcer","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Dermatitis allergic","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Haemorrhage subcutaneous","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Increased tendency to bruise","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Petechiae","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Rash papular","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Skin exfoliation","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":18,"numAtRisk":235},{"groupId":"EG001","numAffected":8,"numAtRisk":233}]},{"term":"Blood lactate dehydrogenase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":235},{"groupId":"EG001","numAffected":2,"numAtRisk":233}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Weight increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Blood glucose increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":2,"numAtRisk":233}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Bacterial test positive","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Blood magnesium increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Blood phosphorus decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Blood phosphorus increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Blood urea increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Blood uric acid increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Body temperature increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Breath sounds abnormal","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"International normalised ratio increased","organSystem":"Investigations","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Vision blurred","organSystem":"Eye disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":235},{"groupId":"EG001","numAffected":8,"numAtRisk":233}]},{"term":"Visual acuity reduced","organSystem":"Eye disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":235},{"groupId":"EG001","numAffected":2,"numAtRisk":233}]},{"term":"Visual impairment","organSystem":"Eye disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":2,"numAtRisk":233}]},{"term":"Asthenopia","organSystem":"Eye disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Blindness","organSystem":"Eye disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Conjunctivitis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Eye inflammation","organSystem":"Eye disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Eye pain","organSystem":"Eye disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Myopia","organSystem":"Eye disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Retinal vascular disorder","organSystem":"Eye disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Vertigo","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":235},{"groupId":"EG001","numAffected":3,"numAtRisk":233}]},{"term":"Tinnitus","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Ear pain","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Ear pruritus","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Auricular swelling","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Deafness","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Hearing impaired","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Hypoacusis","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":2,"numAtRisk":233}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Flushing","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Phlebitis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Haematoma","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Hot flush","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Orthostatic hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Thrombophlebitis superficial","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Coagulopathy","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Pancytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":235},{"groupId":"EG001","numAffected":2,"numAtRisk":233}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":3,"numAtRisk":233}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Palpitations","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Angina pectoris","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Sinus tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Supraventricular extrasystoles","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Dysuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Pollakiuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Chromaturia","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Incontinence","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Nephrolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Proteinuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Urinary bladder haemorrhage","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Urinary incontinence","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Urinary retention","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Cancer pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":235},{"groupId":"EG001","numAffected":3,"numAtRisk":233}]},{"term":"Tumour pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Lung neoplasm malignant","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Metastases to skin","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Non-small cell lung cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Thermal burn","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Incision site pain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Overdose","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Radiation skin injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Skin wound","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Cushingoid","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":1,"numAtRisk":233}]},{"term":"Inappropriate antidiuretic hormone secretion","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Epididymitis","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Prostatitis","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]},{"term":"Hepatic function abnormal","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":235},{"groupId":"EG001","numAffected":0,"numAtRisk":233}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."},"pointOfContact":{"title":"GSK Response Center","organization":"GlaxoSmithKline","phone":"866-435-7343"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D019772","term":"Topotecan"},{"id":"D002214","term":"Capsules"},{"id":"D011827","term":"Radiation"}],"ancestors":[{"id":"D002166","term":"Camptothecin"},{"id":"D000470","term":"Alkaloids"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D004304","term":"Dosage Forms"},{"id":"D004364","term":"Pharmaceutical Preparations"},{"id":"D055585","term":"Physical Phenomena"}]}},"hasResults":true}